Preprint
Review

This version is not peer-reviewed.

Modulatory Effects of Bioactive Phytoconstituents on the Amplitude and Gating Properties of Membrane Ion Channels

Submitted:

03 March 2026

Posted:

04 March 2026

You are already at the latest version

Abstract
This review provides a comprehensive overview of the modulatory actions of plant-derived constituents on membrane ion channels in various cell types. Among their diverse bioactivities, ion channel regulation—governing membrane excitability, signal transduction, and cellular homeostasis—has emerged as a critical mechanistic basis for their pharmacological effects. Twenty-four representative phytoconstituents are discussed and classified into five major categories based on their structural features: alkaloids, terpenoids, lignans and acetogenins, polyphenols, and other aromatic and conjugated compounds. Across these categories, the reviewed compounds exhibit distinct and often highly specific effects on the amplitude and gating kinetics of multiple ionic currents, including voltage-gated Na+ currents (INa), delayed-rectifier K+ currents (IK(DR)), M-type K+ currents (IK(M)), hyperpolarization-activated cation currents (Ih), erg-mediated K+ currents (IK(erg)), inwardly rectifying K+ currents, and Ca2+-activated K⁺ currents (IK(Ca)). Alkaloids predominantly suppress voltage-gated K+ currents, with notable exceptions such as aconitine, which alters the properties of both INa and IK(DR), thereby contributing to its proarrhythmic toxicity. Terpenoids, including cannabidiol, croton diterpenoids, lutein, thymol, and triptolide, exert multifaceted effects on IK(M), Ih, inwardly rectifying K+ currents, and Ca2+-activated K⁺ channels. Lignans and acetogenins, such as gomisin A, honokiol, sesamin, and squamocin, primarily modulate INa, Ih, and IK(Ca), with several compounds demonstrating strong links between ion-channel modulation and anti-neoplastic or neuroprotective actions. Polyphenolic compounds, including curcumin, eugenol, resveratrol, gastrodigenin, gastrodin, and pterostilbene, display diverse ion-channel targeting profiles, influencing multiple Na⁺ and K⁺ channel subtypes. Other aromatic or conjugated compounds, such as isoplumbagin, plumbagin, and verteporfin, regulate IK(erg) and IK(Ca), potentially contributing to both therapeutic efficacy and adverse effects. Collectively, the compound-specific modulation of current amplitude and gating kinetics offers valuable mechanistic insight into the pharmacological and toxicological significance of plant-derived natural products, highlighting the functional role of ion channel evaluation in guiding their therapeutic development and ensuring safety assessment.
Keywords: 
;  ;  ;  ;  ;  

1. Introduction

Plant-derived natural products, often referred to as phytochemicals, are secondary metabolites that plants produce to protect themselves from environmental stress, pests, and diseases. These compounds provide humans with a vast repertoire of bioactive properties that may contribute to the prevention or treatment of a wide range of diseases and disorders [1,2,3,4]. Among these bioactive properties, their regulatory effects on ion channels in the cell membranes of different cell types have long been an important subject of academic research. This review paper examines 24 phytoconstituents derived from plant natural products. Based on their major structural features, these compounds are broadly classified into five main categories: alkaloids, terpenoids, lignans and acetogenins, polyphenols, and other aromatic and conjugated systems (Figure 1). We present a comprehensive overview of the currently recognized modulatory effects of these compounds on membrane ion channels across a broad range of mammalian cell types.

2. Alkaloids

2.1. Aconitine

Aconitine is an intensely poisonous alkaloid derived from plants of the genus Aconitum (Ranunculaceae) [5,6]. This compound is a proarrhythmic agent known to open tetrodotoxin-sensitive Na+ channels in electrically excitable cells [7]. Aconitine-containing herbal extracts have also been reported to exert inhibitory effects on the proliferation of various neoplastic cells [6,8]. Studies have reported that this compound suppresses the delayed-rectifier K+ current (IK(DR)) in neurons, cardiomyocytes, and immune cells, leading to current inactivation upon membrane depolarization [9,10,11,12,13]. Recent findings indicate that aconitine can induce both early and delayed afterdepolarizations in neonatal cardiac cells and can trigger ventricular polymorphic tachycardia in rats [10,13]. These findings underscore the importance of understanding the electrophysiological impact of aconitine and similar compounds, considering their potential therapeutic applications and associated toxicities. Prior to evaluating the therapeutic potential of Aconitum extracts, such as their antitumor effects, it is essential to thoroughly assess the possible toxicities associated with these reagents.

2.2. Arecoline

Areca nut (Areca catechu, family Arecaceae) has long been used as a medical and psychoactive stimulant in China [14] and a leading cause of oral cancer. Arecoline (1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxylic acid methyl ester) is an alkaloid extracted from areca nut and is a non-selective agonist of muscarinic receptors and that has been shown to have carcinogenicity, cytotoxicity and immunotoxicity [15,16].
The neuroprotective effects of arecoline were found in Alzheimer’s disease [17]. It stimulates production of connective tissue growth factors in human buccal mucosal fibroblasts and induces the apoptosis of HaCaT keratinocytes [15,16]. An earlier report has demonstrated that in U373 and U87MG glioma cells, arecoline produces an inhibitory effect on intermediate-conductance Ca2+-activated K+ (KCa3.1-encoded, or KCNN4-encoded) channels in a concentration-, voltage- and state-dependent fashion [18]. The dissociation constant for arecoline-induced suppression of these channels was calculated to be 11.2 M [18]. Arecoline-mediated membrane depolarization can arise primarily from its inhibition of intermediate-conductance Ca2+-activated K+ channels in these cells. Moreover, the major effect of arecoline on these channels is thought to be independent of binding to muscarinic receptor(s) [18]. Compounds like arecoline aimed block KCa3.1 channels could be tailored to become intriguing agents that potentiate the efficacy of other cytotoxic drugs for management of malignant gliomas or other types of neoplastic diseases [19].

2.3. Berberine

Berberine is an isoquinoline alkaloid found in many medicinal plants of the genera Berberis (Berberudaceae) and Coptis (Ranunculaceae). Preparations from these medicinal plants have been used as folk medicine in the treatment of jaundice, dysentery, hypertension, and other diseases [20]. Berberine alone was reported to possess anti-proliferative effects on human teratocarcinoma and hepatoma cells [21].
An earlier study reported that in human myeloma cells, berberine directly and differentially inhibits delayed-rectifier K+ current (IK(DR)) and Ca2+-activated K+ current (IK(Ca)) in a concentration-dependent manner [22]. Berberine also effectively suppresses the proliferation of these cells. Because of the similarity between the potency and IC50 for blocking K+ currents and inhibiting cell proliferation by berberine, the results suggest that inhibition of IK(DR) and IK(Ca) could be one of the mechanisms underlying berberine-induced anti-neoplastic actions [22]. In addition to its suppression of ion channels, berberine was reported to improve mitochondrial function and to increase apoptotic proteins, including cytochrome c, Bax, and caspase [23]. Therefore, berberine is a bioactive compound with potential for the treatment of various diseases, including glioma and Alzheimer’s disease [24,25,26].

3. Terpenoids

3.1. Cannabidiol

Cannabidiol, which is considered a terpenophenol, is a non-psychoactive cannabinoid derived from the Cannabis plant (Cannabaceae), known for its potential therapeutic effects. It is among over 100 cannabinoids present in the plant and has been shown to be effective in treating various medical conditions, such as epilepsy, bipolar disorder, inflammation, and cancer [27]. Recent studies have demonstrated that cannabidiol influences the activity in the hypothalamic-pituitary-adrenal axis and modulates several ionic currents in excitable cells, including voltage-gated Na+ currents (INa), M-type K+ currents (IK(M)), and hyperpolarization-activated cation currents (Ih) [28,29,30].
Cannabidiol exposure was noted to result in a concentration-dependent suppression of IK(M) in pituitary GH3 lactotrophs, with an IC50 of 3.6 M [30]. This compound also results in the suppression of Ih in the same cell type with an IC50 of 3.3 M [30]. These findings suggest that the responsiveness of these ionic currents is complex and influenced by various factors, including the resting membrane potential, cannabidiol concentration, patterns of action potential firing, or combinations of these variables [30].

3.2. Ent-Kaurane-Type Diterpenoids

The genus Croton (Euphorbiaceae) includes about 1300 species that are widely distributed throughout tropical regions. C. tonkinensis Gagnep., known as Kho sam cho la in Vietnamese, is a tropical shrub native to northern Vietnam and has been used commonly in Vietnam to treat different disorders [31]. C. tonkinensis is a rich source of diterpenoids [31], and its extracts were reported to exert anti-inflammatory and cancer chemopreventive activities [31,32].
Studies have shown that the fractions isolated from C. tonkinensis—specifically croton-01 (ent-18-acetoxy-7-hydroxykaur-16-en-15-one), croton-02 (ent-7,14-dihydroxykaur-16-en-15-one), and croton-03 (ent-1-acetoxy-7,14-dihydroxykaur-16-en-15-one)—are capable of modulating ionic currents in microglial SM826 cells, including the IK(DR) (encoded by KV1.3) and the inwardly rectifying K+ current (encoded by Kir2.1) [33]. The notable findings showed that in these microglial cells, croton-03 differentially suppresses KV1.3- and Kir2.1-encoded currents in a concentration-, time-, and state-dependent manner. Voltage-dependent blocking by croton-03 of KV1.3-encoded current with Kd (apparent affinity constant) and  (fractional electrical distance) values of 5.17 M and 0.091, respectively, was also estimated [33]. Therefore, the presence of these ent-kaurane diterpenoids is likely to disrupt cellular function by modulating the activity of these ionic currents.
Another report further demonstrated that the presence of croton-01, croton-02, and croton-03 produces concentration-dependent inhibition of Ih in pituitary tumor (GH3) cells with effective IC50 values of 2.89, 6.25, and 2.84 M, respectively [34]. Cell exposure to croton-03 was also noted to decrease the voltage-dependent hysteresis of this current in response to long-lasting isosceles triangular ramp pulse [34]. Therefore, croton derivatives and other structurally related ent-kaurane-type diterpenoids could represent intriguing compounds that use the open/activated state of the HCN channels as a substrate.

3.3. Lutein

Lutein (xanthophyll, ,-carotene-3,3’-diol), derived from a hydride of a (6R)-,-carotene, is one of the few xanthophyll carotenoids that is recognized to exist not only in vegetables and fruits, but also in high concentrations present in the macula of the human retina, where it is thought to act as a yellow filter [35,36]. A previous study showed that in pituitary GH3 cells, the exposure to lutein is capable of suppressing hyperpolarization-activated cation current in a concentration-, state-, voltage-, and hysteresis-dependent manner [37]. A hyperpolarizing shift of the steady-state activation curve of hyperpolarization-activated cation current was also observed in the presence of lutein.
Furthermore, the subsequent addition of oxaliplatin or ivabradine, but still in the continued presence of 3 M lutein, was capable of adjusting lutein-perturbed inhibition of Ih in GH3 cells, as shown in Figure 2. Oxaliplatin or ivabradine has been shown to activate or suppress Ih, respectively [38,39,40]. Cyclic nucleotide-gated (CNG) channels (e.g., CNGA2 ion channels) were previously shown to exhibit hysteretic behavior of ion currents [41]. As shown in Figure 3, the experimental results disclosed the capability of Ih strength evoked by double ramp pulse to modify the varying patterns of bursting firing in different excitable cells, including central neurons [37,42].
In these current measurements, the tested cell was held at −40 mV and a long-lasting inverted double ramp pulse was applied [37]. The ramp pulse protocol comprises the downsloping (forward) ramp from −40 to −150 mV followed by the upsloping (backward) limb back to −40 mV, with a total duration of 3.2 sec (i.e., a ramp speed of ±69 mV/sec) as indicated in the upper part of Figure 3A. As demonstrated in Figure 3, the voltage-dependent hysteresis of Ih (i.e., the relationship of forward or backward Ih versus membrane potential) was observed upon activation by triangular double ramp pulse [43]. Notably, the Ih amplitude evoked by the downsloping phase of the inverted triangular ramp pulse was smaller (in absolute value) than that elicited by the upsloping phase, as indicated in the dashed arrows along the current trajectory (Figure 3A). For example, in the control (i.e., lutein was not present), the Ih amplitude at −120 mV taken during the downsloping or upsloping phase of double ramp pulse was markedly different (p < 0.05) (i.e., 48 ± 8 pA [downsloping] versus 249 ± 11 pA [upsloping], n = 7, p < 0.05). Under cell exposure to lutein (3 M), Ih evoked in the downsloping limb of the inverted double ramp pulse was found to decline to a lesser extent than that measured from the upsloping end of the triangular ramp pulse. Moreover, the strength of lutein-induced current inhibition at the downsloping (forward) and upsloping (reverse) limbs of triangular ramp pulse differed significantly. As demonstrated in Figure 3B, the degree of Ih’s hysteresis residing in GH3 cells with or without the presence of lutein was further quantified. The results showed the effects of lutein and lutein plus ivabradine on the ∆area under the curve (i.e., the shaded region in A) [37]. For example, in addition to its depressive action on Ih magnitude, the addition of 3 μM lutein resulted in a reduction in the area responding to inverted triangular ramp pulse, as demonstrated by a reduction of ∆area from 17.7 ± 2.4 to 8.8 ± 1.6 mV·nA (n = 7, p < 0.05). After the lutein was removed, the hysteretic area returned to 17.2 ± 2.3 mV·nA. As cells were continually exposed to 3 μM lutein, subsequent application of 3 μM ivabradine measurably decreased the ∆area of voltage-dependent hysteresis further.
The investigators further switched to current-clamp potential recordings in order to examine effects of lutein on sag potential in GH3 cells [37]. Sag potential evoked in response to hyperpolarizing current stimulus has been shown to be closely linked to the presence of Ih in different types of excitable cells [43,44,45,46]. As shown in Figure 4, when the whole-cell potential recordings were achieved, a long-step 2-sec hyperpolarizing current injection with the amplitude of around 25 pA was noticed to induce the occurrence of sag potential (i.e., an abrupt drop-down to a lower level in the membrane potential upon hyperpolarizing current injection) [45]. Cell exposure to ivabradine (3 μM) was effective at suppressing the amplitude of sag potential. Furthermore, the application of 1 or 3 μM lutein resulted in a considerable depression of sag potential evoked in response to hyperpolarizing current stimulus [37]. Together, the findings can be interpreted to mean that, besides its antioxidative or anti-inflammatory properties [47], the existence of lutein can inhibit the amplitude as well as alter gating and hysteretic behavior of Ih, and that lutein’s actions on ionic currents would engage in the modifications of spontaneous action potentials present in electrically excitable cells, presuming that similar in vivo observations occur [37].

3.4. Thymol

Thymol, a monoterpenoid phenol derived from thyme (Thymus vulgaris, Lamiaceae) essential oil, has been widely used as an antiseptic and antimicrobial agent [48,49,50,51]. Its aromatic properties make it a common ingredient in mouthwashes and dental preparations for treating oral infections [48]. Beyond oral care applications, thymol serves as a stabilizer in several therapeutic agents, including the anesthetic halothane, where accumulates in vaporizers during prolonged use. Notably, adverse effects following massive mouthwash ingestion have been attributed to thymol [52,53].
Previous studies have revealed that its biological activities may be partly mediated through modulation of ion channels. In particular, previous studies indicate that thymol influences Ca2+ signaling in pituitary GH3 cells by enhancing capacitative Ca2+ entry and depleting intracellular Ca2+ stores, involving both thapsigargin–sensitive and thapsigargin–insensitive pools [54]. Moreover, thymol was reported to stimulate IK(Ca) in GH3 cells [55]. These stimulatory effects on Ca2+ dynamics may contribute to the cellular mechanisms underlying the impact of thymol on neuroendocrine or endocrine functions.

3.5. Triptolide

Triptolide is a diterpene triepoxide isolated from traditional Chinese medicinal vine Trypterygium wilfordii Hook. F. (Celastraceae). It possesses multiple biological activities, including antitumor, immunosuppression, and antifertility effects [56]. Triptolide can protect neurons in the CNS and promote axon growth of dopaminergic neurons [57]. It also promotes spinal cord repair through down-regulation of astrogliosis and inflammation in an animal model of spinal cord injury [58]. This compound has been reported to inhibit proliferation and invasion of malignant glioma cells [59] and induce apoptotic cell death in malignant glioma cells [60]. Due to its small size and high lipid solubility, triptolide can cross the blood-brain barrier and produce significant effects on glial and glioma cells [56,60].
Previous studies showed that in human glioma cells (U373 cells), triptolide inhibits the inwardly rectifying K+ current in a concentration-dependent manner with an IC50 of 0.72 M [61]. Triptolide suppresses the activity of the inwardly rectifying K+ channels in these cells with no change in single-channel conductance. The biophysical properties of the inwardly rectifying K+ currents in U373 cells resemble the Kir4.1-encoded current because of positive mRNA detection of KCNJ10 (Kir4.1) and high sensitivity to inhibition by BaCl2. KCNJ10, the gene that codes for Kir4.1, is recognized as a putative seizure susceptibility gene in mice and humans [62]. Therefore, the pharmacological actions of triptolide as described recently [56,57,58,59,60] could be partly, if not entirely, connected with its inhibition of the inwardly rectifying K+ channels in glial or glioma cells. However, it should be noted that mRNA expression for other Kir channels may also occur in U373 cells.
We conducted a detailed analysis of the atomic interaction between the KCNJ10 protein [63] and triptolide using PyRx software, employing its embedded AutoDock function. Figure 5 illustrates the predicted docking sites of the triptolide molecule. Notably, during the docking analysis with the KCNJ10 channel, triptolide was observed to form hydrogen bonds with residues Arg36(A) and Ile179(A), with bond lengths of 3.08 and 3.06 Å, respectively. Moreover, triptolide exhibited hydrophobic interactions with several residues, including Lys33(A), Asp34(A), Glu177(A), Arg180(A), Phe181(A), Gln183(A), and Thr198(A). These findings suggest a strong binding affinity between triptolide and the amino acid residues of the KCNJ10 channel, estimated at −7.8 kcal/mol. This interaction predominantly occurs within the intracellular domain of chain A in the KCNJ10 channel. This predicted interaction therefore raises the possibility that triptolide-mediated alterations in the magnitude and gating kinetics of the inwardly rectifying K+ currents may occur independently of its binding to muscarinic receptors [61].

4. Lignans and Acetogenins

4.1. Gomisin A

Gomisin A (wuweizichu B, wǔwèizi chún yĭ), a dietary dibenzocyclooctadiene lignan compound isolated from the hexane fraction obtained from the fruits of Schisandra chinensis (Schisandraceae) [64], has been reported to have anti-inflammatory, anti-oxidative, antihypertensive, neuroprotective, and anti-proliferative properties [65]. For example, this compound was previously reported to induce protective effects either against hepatic and renal injury induced by CCl4 exposure, or nitropropionic acid-induced striatal toxicity, through differential regulation of the MAPK signal transduction pathway [66,67]. It could inhibit COX-2, iNOS, IL-6, TNF- and NOּ through the down-regulation of RIP2 and NF-B activation in mouse macrophages [68]. Earlier reports have also shown that gomisin A was able to exert antioxidative effects during osteoblast differentiation and in vascular endothelial cells [65,69], and to induce apoptotic changes in colon carcinoma HCT-116 cells [70]. Alternatively, the active components of S. chinensis were recently demonstrated to be detected after the intragastric administration of the lignans in rats [64]. The effectiveness of crude S. chinensis extract in decreasing prolactin production in pituitary GH3 cells suggest that such extract could be therapeutically beneficial for patients with hyperprolactinemia and prolactinoma [71].
An interesting report demonstrated that the presence of gomisin A was able to produce an inhibitory action on INa in GH3 cells in a concentration-, a time- and state-dependent manner. Cell exposure to gomisin A was also noticed to accentuate the inactivation rate of voltage-gated Na+ current (INa), particularly at the slow component of current inactivation [72]. The inhibitory action on INa tended to be rapidly developing and readily washed out, and it would concurrently correlate in time with a significant rise in the inactivation rate of the current activated by short depolarizing pulse, while the activation kinetics of INa remained unchanged in the presence of gomisin A. In pituitary GH3 cells, gomisin A differentially and effectively inhibited the transient or late components of INa with effective IC50 value of 6.2 or 0.73 M, respectively [72]. The observed effect of gomisin A on the strength and gating of INa is primarily ascribed to this molecule acting largely on the voltage-gated Na+ (NaV) channel itself or its accessory subunits.
Next, the SCN9A (NaV1.7) protein was docked with gomisin A using PyRx software. The predicted binding sites of gomisin A on this channel protein are illustrated in Figure 6. This compound establishes hydrophobic interactions with several residues, including Ser32(I), Ser820(B), Val821(B), Leu875(A), Phe876(A), Val914(A), Tyr915(A), Pro916(A), and Tyr917(A), which are located in the membrane-embedded segment of the channel. Since the results have shown an inhibitory effect of gomisin A on INa and a predicted interaction between SCN9A protein and gomisin A, this compound could potentially be applied to modulate the activity of NaV1.7 channels in different cell types, thereby influencing their functional activity.

4.2. Honokiol

Honokiol, a hydroxylated biphenyl compound obtained from Magnolia officinalis and from other species (Magnoliaceae), has been used in traditional Asian medicines (Houpo, Hou p’u, or Saiboku-to) [73]. Honokiol is recognized to be a potential natural compound that has been demonstrated to exert multiple effects on different cellular processes in various cancer models [74]. Previous studies have also revealed the effectiveness of this compound in modulating the functional activities of neuroendocrine or endocrine cells. For example, an earlier study has demonstrated that honokiol could induce cell cycle arrest and programmed cell death in vitro and in vivo in human thyroid neoplastic cells [75]. Several investigations have also reported the ability of M. officinalis bark or honokiol to modify the secretion of catecholamines from adrenal chromaffin cells [76]. Moreover, honokiol was noted to exert antidepressant effects by normalizing the hypothalamic-pituitary-adrenal axis [77].
Previous studies have demonstrated that the presence of honokiol produces concentration-dependent inhibition of Ih in GH3 cells with an IC50 value of 2.1 M (Figure 7) [78]. Honokiol shifts the steady-state activation curve of Ih toward a more negative potential with no modification in the gating charge of the current. This compound was able to attenuate the voltage-dependent hysteresis of Ih elicited by long-lasting triangular ramp pulse. It can also depress Ih amplitude in Rolf B1.T olfactory neurons [78]. The results unveiled the evidence that the honokiol presence is effective at inhibiting Ih in pituitary GH3 cells and in Rolf B1.T olfactory neurons. The inhibition of these ionic currents was noted to be rapid in onset and is hence likely to be responsible for its modulatory action on functional activities in sensory neurons such as Rolf B1.T cells. Such inhibitory actions could lead to modifications in the firing behavior of electrically excitable cells, hence altering neuronal function [78].
To examine how honokiol interacts with the HCN channel protein, we used the structure of HCN3 protein from PDB. The HCN3 channel protein structure was acquired from PDB (PDB ID: 8IO3), and PyRx software was used to see how the honokiol molecule docks into the channel protein. Figure 8 presents the predicted docking sites of honokiol for interaction with amino-acid residues of the HCN3 channel. Specifically, the honokiol molecule was predicted to form hydrophobic contacts with residuals Phe60(D), Tyr89(D), Phe94(D), Ile237(D), and Phe238(D), as well as hydrogen bonds with residuals Ser90(D) and Asp91(D), with estimated distances of 2.95 and 3.10 Å, respectively. It is therefore anticipated that honokiol can interact with HCN channels to modulate the amplitude and gating kinetics of Ih [78].
Recent reports have demonstrated the ability of honokiol to exert antioxidant, anti-inflammatory, neurotrophic, and anti-apoptotic effects [79]. We also conducted a predicted docking analysis between honokiol and superoxide dismutase (SOD). SOD is a key antioxidant enzyme that plays a central role in controlling oxidative stress and modulating inflammation. We explored how SOD protein could be optimally docked with honokiol molecule by using PyRx software. The protein structure of SOD was obtained PDB (PDB ID: 1DO5). The predicted docking sites of the honokiol molecule with which the amino-acid residues can interact are presented in Figure 9. Notably, the honokiol molecule was predicted to form hydrophobic contacts with certain residues, including Asn142(B), Asn142(C), Ser143(B), Ser143(C), Gly145(C), Asn146(C), Ser233(A), Ala234(A), Gly235(A), and Leu236(A). The honokiol molecule was also predicted to form a hydrogen bond with residue Asp136(B) with a distance of 2.79 Å. These docking results suggest that honokiol can bind to SOD protein with a binding affinity of −7.4 kcal/mol.

4.3. Ganoderma Triterpenoids

Ganoderma mushrooms (Língzhī in Chinese, or Reishi in Japanese) are a traditional Chinese herbal medicine that has been widely accepted as a nutritional supplement around the world. Among many species of the mushrooms, Ganoderma lucidum (Ganodermataceae) is most commonly used and it is commercially cultivated under controlled conditions to obtain mushrooms with more consistent chemical composition [80]. G. lucidum was reported to possess a variety of biological activities, such as antihypertensive, hypoglycemic, and hypocholesterolemic activities among other medicinal benefits [80,81]. The primary bioactive compounds were noted to include triterpenoids [81,82]. G. lucitum was also shown to prevent cardiac damage in animal models by alleviating the oxidative stress associated with myocardial injury [83].
Triterpenes are types of terpenes having a basic skeleton of C30 carbons. Triterpenoids have molecular weights ranging from 400 to 600 Da, and their chemical structure is complex and noted to be highly oxidized [84]. The triterpenoid fraction of Ganoderma, consisting of more than 300 lanostane triterpenoids, has been increasingly demonstrated to be effective at exerting biological actions, including providing effective antioxidant activities for prevention of myocardial injury, and producing neuroprotective actions [81,83,85]. Ganoderma triterpenoids could also suppress inflammatory response by directly scavenging the free radicals or systemically enhancing the antioxidant enzymes, thereby lowering lipid peroxidase in chicken livers or mice [83,85]. The aqueous extract was reported to exert anti-convulsant, anti-depressive, anxiolytic and anti-nociceptive actions [86].
Previous work has demonstrated that the inhibition by Ganoderma triterpenoids of Ih in GH3 cells did not simply decrease current magnitude, but also altered the kinetics of the current, thereby indicating that they are able to produce a dose-, time- and state-dependent inhibition of Ih [87]. The steady-state activation curve of Ih in the presence of Ganoderma triterpenoids was shifted along the voltage axis toward the less depolarized potential. The IC50 value for Ganoderma triterpenoids-mediated inhibition of Ih observed in GH3 cells (11.7 g/mL) is comparable to concentrations reported for their antioxidative and neuroprotective effects [81,87]. Such intriguing actions could therefore be of pharmacological relevance and appear to be upstream of its effects on oxidative stress occurring inside the cell [80,81].

4.4. Sesamin and Sesamolin

Sesame seeds and sesame oil obtained from Sesamum indicum (Pedaliaceae) have been recognized as health foods in Asian countries [88]. In comparison with other edible oils extracted from diverse seeds, sesame oil is extremely stable due possibly to the effective antioxidant activities presumably attributed to its abundance of lipid-soluble furofuran lignans such as sesamin and sesamolin [88].
Emerging research has demonstrated that sesamin and sesamolin, the two major furofuran lignans of sesame oil, exhibit multiple biological activities. These include suppression of lipid peroxidation in erythrocytes [89], inhibition of intestinal absorption of cholesterol and hepatic 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase activity [90], prevention of chemically induced mammary cancer, inhibition of 5-desaturase and chain elongation of C18 fatty acids, protection of hypoxic neuronal and PC12 cells by suppressing ROS generation and MAPK activation [91], as well as antihypertensive and cardioprotective effects [92].
Previous studies have shown that sesamin or sesamolin differentially and effectively inhibited the transient and late components of INa in a concentration-dependent manner in pituitary GH3 cells [93]. The IC50 value of sesamin needed to lower the peak and the sustained INa were estimated to be 7.2 and 0.6 M, respectively [93]. The addition of sesamin results in producing a modification of the inactivation kinetics of INa in response to brief depolarization. According to a Markovian model designed from the SCN8A channel adopted previously [93,94], sesamin-induced changes in the gating kinetics of NaV channel could be ascribed to its lowering of the probability of open (O) and open-blocked (OB) states of the channel. The results suggest that the inhibition by sesamin of these ion channels can be one of the ionic mechanisms underlying its remarkable changes in the functional activities of different types of electrically excitable cells, assuming that similar observations can be found in vivo [93]. Sesamin and other structurally similar compounds may serve as modulatory agents of NaV channels in neoplastic or neuroendocrine tumor cells within the field of cancer neuroscience, thereby suppressing tumor invasiveness and metastasis [95].

4.5. Squamocin

Squamocin is a bis-tetrahydrofuran acetogenin isolated from several genera of the plant family Annonaceae, including Annona squamosa (custard apple), Annona muricata (soursop), and Asimina triloba (pawpaw). Its structure is characterized by a long, alkyl chain bearing a terminal ,-unsaturated -lactone ring, two tetrahydrofuran rings, and some oxygenated substituents along the chain. Squamocin is known to possess insecticidal properties [96] and anti-tumor effects [97]. Squamocin has been shown to inhibit the activity of mitochondrial NADH:ubiquinone oxidoreductase [98]. In addition, the cytotoxicity caused by asimicin, an analogue of squamocin, was thought to be associated with the regulation of membrane conformation [99]. It has recently been reported that squamocin could induce apoptosis in HL-60 leukemia cells and this effect was implicated in the activation of stress-activated protein kinase [100].
Previous studies reveal an interesting finding that squamocin produces a stimulatory effect on IK(Ca) in human coronary smooth muscle cells [101]. The stimulatory effect on IK(Ca) caused by squamocin was presumably related to changes in the level of intracellular Ca2+ concentrations. The results showing that the removal of extracellular Ca2+ inhibited the squamocin-induced increase in IK(Ca) amplitude, also suggest that both extracellular Ca2+ and internal Ca2+ release contribute to the increase in the current amplitude in these cells. It is likely that squamocin opens membrane ion channels with high Ca2+ permeability, can presumably account for its stimulatory effect on IK(Ca) [101]. The elucidation of the mechanisms by which the actions of squamocin and other structurally related compounds in different types of cells occur remains the aim of further research.

5. Polyphenols

5.1. Curcumin

Curcumin (diferuloylmethane, 1E,6E-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6- heptadiene-3,5-dione), a major constituent of the spice turmeric obtained from Curcuma longa (Zingiberaceae), is a bright yellow diarylheptanoid produced by some plants. It is the principal curcuminoid of turmetic, which is a member of the ginger family (Zingiberaceae). This compound is largely used as a herbal supplement, cosmetics ingredient, food flavoring and food coloring [102]. Particularly, this nutraceutical compound has been demonstrated to possess beneficial properties in a variety of diseases ranging from cancer to diabetes mellitus [103]. For example, curcumin has been recently reported to influence insulin release from isolated pancreatic islets [104].
Curcumin has been reported to exert a concentration- and state-dependent depressant action on IK(DR) in pancreatic -cells, particularly in the rat insulinoma cell line INS-1 [105]. The inhibitory action on this K+ current tends to correlate in time with a significant increase in the inactivation rate of the currents in response to membrane depolarization, while the activation kinetics of the current remained unaltered in the presence of curcumin [105].
The estimated peak of plasma curcumin concentration was previously reported to reach 3.14 g/mL (around 8.57 M) [106], a value which is apparently greater than the KD (1.26 M) and IC50 (3.32 M) required for curcumin-mediated inhibition of IK(DR) seen in INS-1 cells [105]. Therefore, the inhibitory effects of curcumin and curcuminoids on these K+ currents in pancreatic -cells are expected to occur at concentrations achievable in the human organisms, although whether the effects of curcumin and other curcuminoid derivatives on ionic currents in humans still remains to be further delineated.

5.2. Columbianadin

Columbianadin is one of the main bioactive constituents isolated from the underground part of Angelica pubescens Maxim. f. biserrata Shan et Yuan (Apiaceae) (Angelicae Pubescentis Radix, or “Duho [Dú huó]” in China). Columbianandin is a coumarin-type compound (an angular dihydrofuranocoumarin) which is recognized to have various biological activities that include analgesic, anti-inflammatory and anti-neoplastic effects [107,108]. This compound has been reported to induce changes in cellular proliferation or apoptosis [108]. It has also been previously demonstrated that carrageenan and lipopolysaccharide-induced inflammatory reaction are ameliorated by the application of columbianadin [107].
It is important to note that the presence of columbianadin could depress INa in a concentration-, time-, and state-dependent manner in GH3 cells [109]. This compound was found to differentially inhibit the peak and late amplitudes of INa activated by rapid membrane depolarization with effective IC50 values of 14.7 and 2.8 M, respectively [109]. It can shift the midpoint of the INa inactivation curve along the voltage axis to a more negative potential, despite its inability to alter the activation curve of the current. Subsequent addition of columbianadin was capable of depressing the tefluthrin-induced increase in the amplitude of persistent INa activated by the upright isosceles-triangular ramp at either upsloping or downsloping phase. Tefluthrin, a pyrethroid insecticide, can simulate INa [110,111,112]. In HL-1 cardiomyocytes, columbianadin was effective at depressing INa as well as at decreasing the slow component of the inactivation time constant of the current [109]. The experimental results suggest that columbianadin-mediated changes in the amplitude and gating kinetics of ionic currents tend to be upstream of its action either on cytosolic NOD1/NF-B activation [113] or on the activity of antioxidant enzymes [114], and that they could conceivably participate in the adjustments of different functional activities in electrically excitable cells (e.g., GH3 cells or HL-1 cardiomyocytes) occurring in vivo.

5.3. Eugenol

Eugenol (4-allyl-2-methoxyphenol) is an aromatic molecule found in several plants including clove (Syzygium aromaticum, Myrtaceae), bay leaves (Laurus nobilis, Lauraceae), and allspice (Pimenta dioica, Myrtaceae), and has been used in dental practice to relieve pain arising from a variety of sources, such as pulpal inflammations and dentin hypersensitivity [115]. Furthermore, eugenol is neuroprotective against excitotoxicity, cerebral ischemia and the toxic effects of amyloid- peptides [116,117]. This compound has been demonstrated to suppress epileptiform field potentials and spreading depression in hippocampus and neocortex. These results suggest that the anti-convulsive properties of eugenol are mediated through the effects on neuronal ion fluxes by blocking NaV channels [118,119,120].
The evidence has emerged that the effects on ion channels may be an important mechanism underlying eugenol-induced actions in neurons. Previous studies demonstrated the ability of eugenol to bind to vanilloid receptors and, in turn, to activate non-selective cation channels [121]. A recent work has also reported that it produced an inhibition of voltage-gated Ca2+ current through CaV2.3 channels in the E52 cell line [122]. Such inhibition is thought to be direct and independent of the binding to vanilloid receptors or to -adrenergic receptors [121,122].
Previous reports have demonstrated that the exposure to eugenol differentially inhibited the transient and late components of INa in differentiated NG108-15 neuronal cells in a concentration-dependent manner [123]. The IC50 values of eugenol required for the inhibition of the transient and late INa were 8.9 and 1.6 M, respectively [123]. Eugenol can also diminish the amplitude of persistent INa evoked by long-lasting ramp pulse, and tefluthrin reversed the eugenol-induced inhibition of this current. This compound could decrease the frequency of spontaneous action potentials. It is therefore anticipated that the observed effects of this agent on ionic currents could be an important mechanism underlying its actions in neurons occurring in vivo [117,120,123].

5.4. Resveratrol

Resveratrol (trans-3,4’,5-trihydroxystilbene), a polyphenolic phytoalexin, is derived from various plants, including grape (Vitis vinifera, Vitaceae), peanuts (Arachis hypogaea, Fabaceae), and various berries. It has been demonstrated that resveratrol displays several pharmacological activities, including anti-platelet, anti-carcinogenic, anti-viral, and cardioprotective effects [124,125,126]. Moreover, there is accumulating evidence indicating that resveratrol exhibits neuroprotective effects [3,125,127]. In fact, resveratrol attenuates kainic acid-mediated convulsion and the associated neurotoxicity and also protects against pentylenetetrazol-induced seizure [128,129].
An important finding has reported that the suppressing effect of resveratrol in rat cortical neurons on action potential firing rate may be mediated by both stimulation of IK(Ca) and suppression of INa [130]. The increased amplitude of IK(Ca) is attributed to the stimulation of large-conductance Ca2+-activated K+ channels [124,130]. Inhibition of INa by resveratrol was reported to account for its analgesic effects [131]. With dual effects on IK(Ca) and INa, resveratrol might have the potential as a broad-spectrum anti-seizure medication.

5.5. Gastrodigenin and Gastrodin

Gastrodigenin (p-hydroxybenzyl alcohol, 4-hydroxybenzyl alcohol) is a phenolic compound found in the traditional Chinese herbal medicine Gastrodia elata Blume (Orchidaceae), which is commonly known as Tian Ma in Chinese or Chunma in Korean [132]. Gastrodin, the glucoside of gastrodigenin, is the major bioactive ingredient which can be isolated from G. elata. In East Asian countries, the dried rhizomes have been widely used for centuries to treat many neurological and psychiatric disorders, including convulsive disorders, dizziness, dementia, depression and migraines [133,134,135,136]. Increasing research is being conducted to determine the underlying molecular mechanisms through which the active constituents of G. elata may exert their pharmacological effects.
Previous studies have evaluated two structurally related compounds, gastrodigenin and gastrodin, for their actions on different types of ionic currents in pituitary cells and hippocampal neurons. In pituitary GH3 lactotrophs, gastrodigenin and gastrodin suppressed the amplitude of IK(M) in a time- and concentration-dependent manner [137]. The IC50 value of gastrodigenin and gastrodin needed to inhibit IK(M) in GH3 cells were estimated to be 12.1 and 19.4 M, respectively [137]. Gastrodigenin-induced inhibition of IK(M) was associated with a slowing of the activation time course of IK(M), while gastrodin-mediated inhibition was associated with an increase in the activation time course of the current. Gastrodigenin shifted the steady-state activation curve of IK(M) toward less depolarized potential with no change in the gating charge of the current [137]. The addition of gastrodigenin or gastrodin also effectively inhibited IK(M) amplitude in hippocampal mHippoE-14 neurons. Therefore, because gastrodin can penetrate through the blood-brain barrier, different types of ionic currents, particularly low-threshold IK(M) with a slowly activating and deactivating properties, may be a relevant target for the regulatory actions of these agents in endocrine or neuroendocrine cells, or central neurons, if similar in vivo findings occur [134,135,136,137].

5.6. Pterostilbene

Pterostilbene (trans-3,5-dimethoxy-4’-hydroxystilbene) is a natural dimethylated analog of resveratrol isolated from Pterocarpus marsupium Roxb. (Fabaceae), a tree native to India, Nepal, and Sri Lanka. The extracts of P. marsupium containing pterostilbene have been traditionally used in Ayurvedic medicine for treating various disorders [138]. This compound has been reported to have benefits for the prevention or treatment of different kinds of cancers, as mounting evidence has demonstrated its inhibitory effects on almost every cellular event that promotes tumor progression toward metastasis in both apoptosis-dependent and apoptosis-independent manners [139,140,141].
In earlier studies, the addition of pterostilbene inhibited Ih effectively in a concentration- and time-dependent manner in pituitary GH3 cells. The I-V relationships of Ih established at various levels of hyperpolarizing steps were also established and depicted in Figure 10. It was noted that the presence of pterostilbene (1 M) significantly reduced the slope of the linear fit of Ih amplitudes to the voltages between −130 and −100 mV from 27.2 ± 1.3 to 13.1 ± 1.1 nS (n = 8, p < 0.05). The steady state activation curve of Ih was distinctly shifted to more hyperpolarizing potentials by 11 mV, producing channel opening at more negative voltages. The results thus demonstrate that pterostilbene has a conceivable depressant action on Ih functionally expressed in GH3 cells [142].
Furthermore, as shown in Figure 11, the presence of pterostilbene raised the amplitude of macroscopic IK(Ca) in GH3 cells. In this set of whole-cell current recordings, GH3 cells were bathed in normal Tyrode’s solution containing 1.8 mM CaCl2, and the recording pipette was filled with a K+-enriched solution. In an attempt to inactivate most of the voltage-gated K+ currents [143], we then maintained the examined cells at the level of 0 mV, and then applied a series of voltage pulses between 0 and +50 mV with 10-mV steps. Within 1 min of exposing GH3 cells to pterostilbene (3 M), the amplitude of IK(Ca) elicited by this voltage profile evidently rose (Figure 11). For example, the addition of 3 M pterostilbene increased IK(Ca) amplitude elicited by depolarizing pulse from 0 to +50 mV from 568 ± 35 to 1005 ± 89 pA (n = 8, p < 0.05). As the compound was washed out, current amplitude returned to 621 ± 38 pA (n = 8). The averaged I-V relationships of IK(Ca) amplitude in the control, during the exposure to 3 M pterostilbene and after washout of the compound were depicted in Figure 11B. The addition of 3 M pterostilbene substantially increased the whole-cell conductance of IK(Ca) measured at the voltages between +30 and +50 mV to 19.6 ± 0.8 nS (n = 8, p < 0.05) from control value of 12.6 ± 0.5 nS (n = 8). Therefore, pterostilbene can increase the amplitude of IK(Ca) observed in these cells and its stimulation of IK(Ca) was largely attributable to the activation of large-conductance Ca2+-activated K+ channels [142].

6. Other Aromatic or Conjugated Systems

6.1. Isoplumbagin and Plumbagin

Isoplumbagin (5-hydroxy-3-methyl-1,4-naphthoquinone) is a naturally occurring quinone from Lawsonia inermis (Lythraceae) or Plumbago europarea (Plumbaginaceae) [144] . Similar to isoplumbagin, plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), another hydroxyl-1,4-napththoquinone, is another alkaloid obtained from the roots of the plants of Plumbago genus. Isoplumbagin and plumbagin have been demonstrated to exert antineoplastic activity against an array of cancer cells, including oral and tongue squamous cell carcinoma, glioblastoma, non-small cell lung carcinoma, and breast, cervical, endometrial, pancreatic and prostate cancers [145,146]. Alternatively, plumbagin was shown to induce apoptotic changes in lung cancer and neuronal cells via caspase-9 activation and targeting mitochondrial-mediated ROS induction [147,148]. Plumbagin has been reported to modify release of pituitary gonadotropin [149]. Previous studies have shown the ability of 2-mercaptophenyl-1,4-naphthoquinone, a naphthoquinone derivative, to overcome the elevation of intracellular Ca2+ in platelets caused by ADP and collagen [150], as well as to suppress the amplitude of IK(Ca) and IK(DR) in GH3 cells [151].
Emerging evidence has shown that isoplumbagin modulates the magnitude, gating kinetics, and voltage-dependent hysteresis of erg (ether-à-go-go-related gene)-mediated K+ currents (IK(erg)) obtained in GH3 cells [152]. In addition, these K+ currents in MA-10 Leydig tumor cells were also found to be blocked by isoplumbagin [152]. The experimental observations suggest that the reduction by isoplumbagin or plumbagin of IK(erg) could potentially contribute to its anti-neoplastic actions, presuming that similar in vivo findings occur.
The IC50 values required for isoplumbagin-mediated block of peak or sustained IK(erg) were 18.3 or 2.4 M, respectively [152]. From the first-order reaction scheme, the KD value was quantitatively calculated to be 2.58 M, a value that was noted to dovetail with the IC50 (i.e., 2.4 M) for isoplumbagin-induced inhibition of sustained IK(erg) evoked by long-lasting membrane hyperpolarization. An earlier study has shown that the isoplumbagin at a concentration of 2.5 M could suppress the activity of mitochondrial respiration through a mechanism of its inhibitory action on complex IV activation [153]. Moreover, any modifications by isoplumbagin or plumbagin of IK(erg) depend not only on the concentration of these compounds given but also on different confounding variables, such as the pre-existing level of the resting potential and various discharge patterns of action potentials or their combinations, presuming that the magnitude of IK(erg) is adequately expressed in the cells examined. Therefore, whatever the detailed mechanism of isoplumbagin-inhibited actions on IK(erg) remains unresolved, the block by isoplumbagin or plumbagin of IK(erg) would be of pharmacological relevance [154]. It is likely that the presence of isoplumbagin or plumbagin may induce prolactin secretion in vivo directly through the inhibition of IK(erg) [155,156]. However, to what extent isoplumbagin-mediated block of IK(erg) affects cardiac function [156,157] remains to be delineated.

6.2. Verteporfin

Verteporfin (Visudyne®), a benzoporphyrin derivative, is a compound therapeutically tailored as a photosensitizer for photodynamic therapy, because this agent can effectively eliminate aberrant blood vessels in the eye associated with conditions such as either the wet form of macular degeneration or abnormal choroidal neovascularization [158,159,160].
The photodynamic therapy with different photosensitizers such as hypericin or verteporfin has been previously demonstrated to be effective in the treatment of different types of hyperplastic or neoplastic tissues, including the residual small tumor in the pituitary gland [161,162]. Previous work indeed reported the capability of photosensitizers (e.g., rose Bengal, a fluorescein-derivative photosensitizer) to modify membrane ionic current in GH3 cells and heart cells [163]. Alternatively, earlier reports have also revealed that verteporfin could induce anterior ischemic optic neuropathy in rodents [158,164].
A previous report discloses important findings showing that verteporfin produced a stimulatory effect on Ca2+-activated K+ current (IK(Ca)) in pituitary GH3 cells; however, it mildly depressed IK(DR) amplitude with no modification of INa or IK(M) [165]. The stimulatory effect on IK(Ca) caused by verteporfin was presumably related to changes in the level of intracellular Ca2+ concentrations. The results showing that removal of extracellular Ca2+ suppressed verteporfin-induced increase in IK(Ca) also suggest that extracellular Ca2+ and internal Ca2+ release both contribute to the increase in the amplitude of IK(Ca) in these cells.
The EC50 value for either verteporfin-induced stimulation of IK(Ca) observed in pituitary GH3 cells or increase in the activity of large-conductance Ca2+-activated K+ channels in 13-06-MG glioma cells (a human glioblastoma multiforme cell line) was estimated to be 2.4 or 1.9 M, respectively [165]. These values are quite close to those that are either therapeutically achievable or required for the inhibitory actions on YAP-TEAD (YAP-TEA domain transcription factor) complex in different types of anaplastic or neoplastic cells [166,167]. Because verteporfin increased IK(Ca) amplitude within minutes in GH3 cells, it is plausible to suggest a mechanistic association between its anti-neoplastic effects and its stimulatory actions on IK(Ca), possibly occurring before the compound passes through the cell membrane [1,165,168].

7. Conclusions

This review illustrates that five major chemical classes of phytoconstituents exert distinct and specific modulatory effects on membrane ionic currents, providing a mechanistic basis for their potential pharmacological activities. Alkaloids predominantly exert inhibitory effects on voltage-gated K⁺ currents; however, aconitine specifically affects the inactivation of INa and IK(DR). Terpenoids modulate IK(M), Ih, and IK(DR). Compounds within the lignan and acetogenin groups exhibit inhibitory actions on INa and Ih. Polyphenolic compounds influence, to varying extents, IK(DR), INa, Ih, IK(erg), IK(M), and IK(Ca). In contrast, other aromatic or conjugated compounds can regulate IK(erg) and IK(Ca). Moreover, individual phytoconstituents also display distinct specificities with respect to both the amplitude and gating kinetics of different ionic currents across various cell types.
Ion channel gating kinetics refers to the dynamic rates governing transitions among the functional states of a channel—closed, open, and inactivated—and encompasses activation, inactivation, deactivation, and recovery kinetics [111,169]. By utilizing electrophysiological techniques—particularly voltage-clamp methods—and incorporating digital-to-analog conversion to generate a variety of voltage-clamp profiles, this approach remains the principal method currently used to investigate voltage-clamp ionic currents [169,170]. The docking predictions also indicate that several amino acid residues within many ion channel structures are capable of forming molecular interactions with various phytoconstituents, including hydrogen bonds and hydrophobic contacts. Collectively, these findings have important pharmacological and toxicological implications for the various bioactivities of individual phytoconstituents [1,2,3,4,171].
In addition, phytoconstituents often modulate ion channel proteins situated on the cell surface or interact with nearby membrane phospholipids. Because these actions occur at or within the plasma membrane, the compounds do not necessarily need to enter the cell. As a result, their effects typically appear rapidly and extremely low concentrations are not required for efficacy [171]. In contrast, when their targets reside within the cytoplasm—such as intracellular signaling pathways—or within the nucleus, where they influence transcriptional or epigenetic processes, the onset of action is generally slower. Access to these intracellular targets requires the compounds to cross the plasma membrane, a process largely determined by their lipid solubility (e.g., reflected by the partition coefficient). Consequently, although some bioactive phytoconstituents appear to demonstrate biological effects at relatively low concentrations in cell-free assays, such as western blotting, immunofluorescent assay, and co-immunoprecipitation [2,3,16,23,24,59,79,100,139], substantially higher concentrations are often required to elicit measurable intracellular responses [171].
It is also important to recognize that, in addition to the phytoconstituents described in this article, numerous other compounds with significant modulatory effects on ion channels are likely to be discovered as electrophysiological methodologies—such as automated patch-clamp recording—continue to advance and gain wider application. Moreover, with the exception of certain ligand-gated channels and transient receptor potential (TRP) channels, voltage-gated ion currents are typically activated either rapidly—within a few milliseconds (e.g., INa)—or more slowly, over seconds (e.g., IK(erg) and Ih) [1,43,169,170]. Moreover, the magnitude, gating kinetics, and voltage-dependent hysteresis of voltage-gated ionic currents vary significantly across different cell types [43,152,154,169,170]. In contrast, antineoplastic or antioxidative effects generally require several hours to become apparent. Therefore, clarifying how rapid modulation of ion channels can ultimately translate into these slower antineoplastic, antioxidative, or immunomodulatory outcomes represents an important direction for future research [1]. Addressing this temporal gap is an important objective for future research and may uncover ion channel activity as an early initiator of subsequent intracellular (cytoplasmic or nuclear) responses [1,171].

Author Contributions

Conceptualization, S.N.W., G.F., Y.J.W., and R.L.; methodology, S.N.W. and Y.J.W.; validation, S.N.W, G.F., and Y.J.W.; formal analysis, S.N.W.; investigation, S.N.W., Y.J.W., and R.L.; resources, S.N.W. and R.L.; data curation, S.N.W., G.F., Y.J.W., and R.L.; writing—original draft preparation, S.N.W..; writing—review and editing, S.N.W. and R.L.; visualization, S.N.W. and G.F.; supervision, S.N.W.; project administration, R.L.; funding acquisition, R.L. All authors have read and agreed to the published version of the manuscript.”.

Funding

This work was supported in part by the National Science and Technology Council, Taiwan (NSTC-112-2923-B-006-0016-028), and by An Nan Hospital, Taiwan (ANHRF112-43 and ANHRF112-44). This research was also funded by the Lithuania-Latvia-Taiwan collaborative project. All conclusions, recommendations, and expressed opinions within this work are based on the authors’ independent research. They do not reflect the official policies or views of the funding organizations or institutions that supported this research.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

The data are available upon reasonable request to the corresponding author.

Acknowledgments

The author (S.N.W.) thanks Professor Dr. Rasa Liutkevičienė for the invitation to visit the Museum of the History of Lithuanian Medicine and Pharmacy, Kaunas, Lithuania, which provided inspiration for this work.

Conflicts of Interest

The authors declare that they have no conflict of interest, financial or otherwise. The content and writing of this paper are entirely the responsibility of the authors.

Abbreviations

The following abbreviations are used in this manuscript:
erg ether-à-go-go-related gene
HCN channel Hyperpolarization-activated cyclic nucleotide-gated channel
IC50 Concentration required for half-maximal inhibition
Ih Hyperpolarization-activated cation current
IK(Ca) Ca2+-activated K+ current
IK(DR) Delayed-rectifier K+ current
IK(erg) erg-mediated K+ current
IK(M) M-type K+ current
INa Voltage-gated Na+ current
NaV (SCN) channel Voltage-gated Na+ channel
I-V relationship Current versus voltage relationship

References

  1. Rao, R.; Mohammed, C.; Alschuler, L.; Pomeranz Krummel, D.A.; Sengupta, S. Phytochemical Modulation of Ion Channels in Oncologic Symptomatology and Treatment. Cancers (Basel) 2024, 16, 1786. [Google Scholar] [CrossRef]
  2. Ansari, P.; Reberio, A.D.; Ansari, N.J.; Kumar, S.; Khan, J.T.; Chowdhury, S.; Abd El-Mordy, F.M.; Hannan, J.M.A.; Flatt, P.R.; Abdel-Wahab, Y.H.A.; Seidel, V. Therapeutic Potential of Medicinal Plants and Their Phytoconstituents in Diabetes, Cancer, Infections, Cardiovascular Diseases, Inflammation and Gastrointestinal Disorders. Biomedicines 2025, 13, 454. [Google Scholar] [CrossRef] [PubMed]
  3. Sonnino, R.; Ciccarelli, G.; Moffa, S.; Soldovieri, L.; Di Giuseppe, G.; Brunetti, M.; Cinti, F.; Di Piazza, E.; Gasbarrini, A.; Nista, E.C.; Pontecorvi, A.; Giaccari, A.; Mezza, T. Exploring nutraceutical approaches linking metabolic syndrome and cognitive impairment. iScience 2025, 28, 111848. [Google Scholar] [CrossRef]
  4. Froldi, G. Bioactivity of Natural Compounds: From Plants to Humans. Molecules 2026, 31, 295. [Google Scholar] [CrossRef]
  5. Pullela, R.; Young, L.; Gallagher, B.; Avis, S.P.; Randell, E.W. A case of fatal aconitine poisoning by Monkshood ingestion. J. Forensic Sci. 2008, 53, 491–494. [Google Scholar] [CrossRef]
  6. Gao, Y.; Fan, H.; Nie, A.; Yang, K.; Xing, H.; Gao, Z.; Yang, L.; Wang, Z.; Zhang, L. Aconitine: A review of its pharmacokinetics, pharmacology, toxicology and detoxification. J. Ethnopharmacol. 2022, 293, 115270. [Google Scholar] [CrossRef]
  7. Wang, S.Y.; Wang, G.K. Voltage-gated sodium channels as primary targets of diverse lipid-soluble neurotoxins. Cell. Signal. 2003, 15, 151–159. [Google Scholar] [CrossRef] [PubMed]
  8. Zhang, Y.; Wang, Y.P.; Guo, S.; Li, T.T.; Wang, Q.Y.; Zhang, X.; Zheng, Y.M.; Wen, Y.Q.; Meng, F.H.; Zhang, T.J. Novel E-F ring derivatives of aconitine scaffold as potent Hsp90 inhibitors for the treatment of colorectal cancer. Eur. J. Med. Chem. 2025, 296, 117895. [Google Scholar] [CrossRef]
  9. Lin, M.W.; Wang, Y.J.; Liu, S.I.; Lin, A.A.; Lo, Y.C.; Wu, S.N. Characterization of aconitine-induced block of delayed rectifier K+ current in differentiated NG108-15 neuronal cells. Neuropharmacology 2008, 54, 912–923. [Google Scholar] [CrossRef]
  10. Wang, Y.J.; Chen, B.S.; Lin, M.W.; Lin, A.A.; Peng, H.; Sung, R.J.; Wu, S.N. Time-dependent block of ultrarapid-delayed rectifier K+ currents by aconitine, a potent cardiotoxin, in heart-derived H9c2 myoblasts and in neonatal rat ventricular myocytes. Toxicol. Sci. 2008, 106, 454–463. [Google Scholar] [CrossRef] [PubMed]
  11. Wu, S.N.; Chen, B.S.; Lin, M.W.; Liu, Y.C. Contribution of slowly inactivating potassium current to delayed firing of action potentials in NG108-15 neuronal cells: experimental and theoretical studies. J. Theor. Biol. 2008, 252, 711–721. [Google Scholar] [CrossRef]
  12. Wu, S.N.; Chen, B.S.; Lo, Y.C. Evidence for aconitine-induced inhibition of delayed rectifier K+ current in Jurkat T-lymphocytes. Toxicology 2011, 289, 11–18. [Google Scholar] [CrossRef]
  13. Chou, C.J.; So, E.C. Effects of aconitine on membrane currents and action potentials in neonatal rat ventricular myocytes and its impact on electrocardiographic changes. Medical Research Archives 2024, 12. [Google Scholar] [CrossRef]
  14. Lee, C.H.; Chiang, S.L.; Ko, A.M.; Hua, C.H.; Tsai, M.H.; Warnakulasuriya, S.; Ibrahim, S.O.; Sunarjo; Zain, R.B.; Ling, T.Y.; Huang, C.L.; Lane, H.Y.; Lin, C.C.; Ko, Y.C. Betel-quid dependence domains and syndrome associated with betel-quid ingredients among chewers: an Asian multi-country evidence. Addiction 2014, 109, 1194–1204. [Google Scholar] [CrossRef]
  15. Li, M.; Gao, F.; Zhou, Z.S.; Zhang, H.M.; Zhang, R.; Wu, Y.F.; Bai, M.H.; Li, J.J.; Lin, S.R.; Peng, JY. Arecoline inhibits epithelial cell viability by upregulating the apoptosis pathway: implication for oral submucous fibrosis. Oncol Rep. 2014, 31, 2422–2428. [Google Scholar] [CrossRef]
  16. Chan, P.K.; Keyes, A.; Papanastasiou, S.; Sarrafpour, B.; Ramaswamy, Y.; Co, S.; Zoellner, H.; Chami, B. Arecoline stimulates the IL-33/13 axis and upregulates pro-fibrotic CTGF: A possible role in oral submucous fibrosis. Food Chem. Toxicol. 2026, 207, 115811. [Google Scholar] [CrossRef]
  17. Lee, S.C.; Tsai, C.C.; Yao, C.H.; Hsu, Y.M.; Chen, Y.S.; Wu, M.C. Effect of arecoline on regeneration of injured peripheral nerves. Am. J. Chin. Med. 2013, 41, 865–885. [Google Scholar] [CrossRef]
  18. So, E.C.; Huang, Y.M.; Hsing, C.H.; Liao, Y.K.; Wu, S.N. Arecoline inhibits intermediate-conductance calcium-activated potassium channels in human glioblastoma cell lines. Eur. J. Pharmacol. 2015, 758, 177–187. [Google Scholar] [CrossRef] [PubMed]
  19. Xu, H.; Lai, W.; Zhang, Y.; Liu, L.; Luo, X.; Zeng, Y.; Wu, H.; Lan, Q.; Chu, Z. Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner. BMC Cancer 2014, 14, 330. [Google Scholar] [CrossRef]
  20. Bova, S.; Padrini, R.; Goldman, W.F.; Berman, D.M.; Cargnelli, G. On the mechanism of vasodilating action of berberine: possible role of inositol lipid signaling system. J. Pharmacol. Exp. Ther. 1992, 261, 318–323. [Google Scholar] [CrossRef] [PubMed]
  21. Chi, C.W.; Chang, Y.F.; Chao, T.W.; Chiang, S.H.; P'eng, F.K.; Lui, W.Y.; Liu, T.Y. Flowcytometric analysis of the effect of berberine on the expression of glucocorticoid receptors in human hepatoma HepG2 cells. Life Sci. 1994, 54, 2099–2107. [Google Scholar] [CrossRef]
  22. Wu, S.N.; Yu, H.S.; Jan, C.R.; Li, H.F.; Yu, C.L. Inhibitory effects of berberine on voltage- and calcium-activated potassium currents in human myeloma cells. Life Sci. 1998, 62, 2283–2294. [Google Scholar] [CrossRef]
  23. Hsu, Y.Y.; Chen, C.S.; Wu, S.N.; Jong, Y.J.; Lo, Y.C. Berberine activates Nrf2 nuclear translocation and protects against oxidative damage via a phosphatidylinositol 3-kinase/Akt-dependent mechanism in NSC34 motor neuron-like cells. Eur. J. Pharm. Sci. 2012, 46, 415–425. [Google Scholar] [CrossRef]
  24. Bian, X.; Guo, Q.; Yau, L.F.; Yang, L.; Wang, X.; Zhao, S.; Wu, S.; Qin, X.; Jiang, Z.H.; Li, C. Berberine-inspired ionizable lipid for self-structure stabilization and brain targeting delivery of nucleic acid therapeutics. Nat. Commun. 2025, 16, 2368. [Google Scholar] [CrossRef]
  25. Zhou, W.; Asif, A.; Situ, C.; Wang, J.; Hao, H. Multiple target and regulatory pathways of berberine. Phytomedicine 2025, 146, 157030. [Google Scholar] [CrossRef] [PubMed]
  26. Moskalev, A.; Veselova, O. Potential dietary geroprotectors and their impact on key mechanisms of aging. Biogerontology 2026, 27, 8. [Google Scholar] [CrossRef] [PubMed]
  27. Britch, S.C.; Babalonis, S.; Walsh, S.L. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl) 2021, 238, 9–28. [Google Scholar] [CrossRef]
  28. Huang, C.W.; Lin, P.C.; Chen, J.L.; Lee, M.J. Cannabidiol Selectively Binds to the Voltage-Gated Sodium Channel Na(v)1.4 in Its Slow-Inactivated State and Inhibits Sodium Current. Biomedicines 2021, 9, 1141. [Google Scholar] [CrossRef] [PubMed]
  29. Ghovanloo, M.R.; Ruben, P.C. Cannabidiol and Sodium Channel Pharmacology: General Overview, Mechanism, and Clinical Implications. Neuroscientist 2022, 28, 318–334. [Google Scholar] [CrossRef]
  30. Liu, Y.C.; So, E.C.; Wu, S.N. Cannabidiol Modulates M-Type K+ and Hyperpolarization-Activated Cation Currents. Biomedicines 2023, 11, 2651. [Google Scholar] [CrossRef]
  31. Giang, P.M.; Son, P.T.; Lee, J.J.; Otsuka, H. Four ent-kaurane-type diterpenoids from Croton tonkinensis GAGNEP. Chem. Pharm. Bull. (Tokyo) 2004, 52, 879–882. [Google Scholar] [CrossRef]
  32. Lee, H.M.; Kuo, P.C.; Chen, W.H.; Chen, P.J.; Lam, S.H.; Su, Y.C.; Chen, C.H. Diterpenoid from Croton tonkinensis as a Potential Radiation Sensitizer in Oral Squamous Cell Carcinoma: An In Vitro Study. Int. J. Mol. Sci. 2024, 25, 11839. [Google Scholar] [CrossRef] [PubMed]
  33. Hsiao, H.T.; Lee, Y.C.; Liu, Y.C.; Kuo, P.C.; Wu, S.N. Differential suppression of delayed-rectifier and inwardly rectifier K+ currents by a group of ent-kaurane-type diterpenoids from Croton tonkinensis, in microglial cells. Eur. J. Pharmacol. 2019, 856, 172414. [Google Scholar] [CrossRef] [PubMed]
  34. Kuo, P.C.; Liu, Y.C.; Lo, Y.C.; Wu, S.N. Characterization of Inhibitory Effectiveness in Hyperpolarization-Activated Cation Currents by a Group of ent-Kaurane-Type Diterpenoids from Croton tonkinensis. Int. J. Mol. Sci. 2020, 21, 1268. [Google Scholar] [CrossRef]
  35. Mitra, S.; Rauf, A.; Tareq, A.M.; Jahan, S.; Emran, T.B.; Shahriar, T.G.; Dhama, K.; Alhumaydhi, F.A.; Aljohani, A.S.M.; Rebezov, M.; Uddin, M.S.; Jeandet, P.; Shah, Z.A.; Shariati, M.A.; Rengasamy, K.R. Potential health benefits of carotenoid lutein: An updated review. Food Chem. Toxicol. 2021, 154, 112328. [Google Scholar] [CrossRef]
  36. Mrowicka, M.; Mrowicki, J.; Kucharska, E.; Majsterek, I. Lutein and Zeaxanthin and Their Roles in Age-Related Macular Degeneration-Neurodegenerative Disease. Nutrients 2022, 14, 827. [Google Scholar] [CrossRef]
  37. Chuang, C.W.; Chang, K.P.; Cho, H.Y.; Chuang, T.H.; Yu, M.C.; Wu, C.L.; Wu, S.N. Characterization of Inhibitory Capability on Hyperpolarization-Activated Cation Current Caused by Lutein (β,ε-Carotene-3,3'-Diol), a Dietary Xanthophyll Carotenoid. Int. J. Mol. Sci. 2022, 23, 7186. [Google Scholar] [CrossRef] [PubMed]
  38. Dini, L.; Del Lungo, M.; Resta, F.; Melchiorre, M.; Spinelli, V.; Di Cesare Mannelli, L.; Ghelardini, C.; Laurino, A.; Sartiani, L.; Coppini, R.; Mannaioni, G.; Cerbai, E.; Romanelli, M.N. Selective Blockade of HCN1/HCN2 Channels as a Potential Pharmacological Strategy Against Pain. Front. Pharmacol. 2018, 9, 1252. [Google Scholar] [CrossRef]
  39. Hsiao, H.T.; Liu, Y.C.; Liu, P.Y.; Wu, S.N. Concerted suppression of Ih and activation of IK(M) by ivabradine, an HCN-channel inhibitor, in pituitary cells and hippocampal neurons. Brain Res. Bull. 2019, 149, 11–20. [Google Scholar] [CrossRef]
  40. Wu, S.N.; Fang, Y.H.; Liu, P.Y.; Liu, Y.W. Characterization of hyperpolarization-induced cation current in differentiated human embryonic stem cell-derived cardiomyocytes. Journal of the American College of Cardiology (JACC) 2020, 75 (Suppl), P31322–X. [Google Scholar] [CrossRef]
  41. Nache, V.; Eick, T.; Schulz, E.; Schmauder, R.; Benndorf, K. Hysteresis of ligand binding in CNGA2 ion channels. Nat. Commun. 2013, 4, 2866. [Google Scholar] [CrossRef] [PubMed]
  42. Barthel, L.; Reetz, O.; Strauss, U. Use Dependent Attenuation of Rat HCN1-Mediated Ih in Intact HEK293 Cells. Cell. Physiol. Biochem. 2016, 38, 2079–2093. [Google Scholar] [CrossRef]
  43. Xiao, Y.F.; Chandler, N.; Dobrzynski, H.; Richardson, E.S.; Tenbroek, E.M.; Wilhelm, J.J.; Sharma, V.; Varghese, A.; Boyett, M.R.; Iaizzo, P.A.; Sigg, D.C. Hysteresis in human HCN4 channels: a crucial feature potentially affecting sinoatrial node pacemaking. Sheng Li Xue Bao 2010, 62, 1–13. [Google Scholar]
  44. Datunashvili, M.; Chaudhary, R.; Zobeiri, M.; Lüttjohann, A.; Mergia, E.; Baumann, A.; Balfanz, S.; Budde, B.; van Luijtelaar, G.; Pape, H.C.; Koesling, D.; Budde, T. Modulation of Hyperpolarization-Activated Inward Current and Thalamic Activity Modes by Different Cyclic Nucleotides. Front. Cell. Neurosci. 2018, 12, 369. [Google Scholar] [CrossRef]
  45. Chang, W.T.; Ragazzi, E.; Liu, P.Y.; Wu, S.N. Effective block by pirfenidone, an antifibrotic pyridone compound (5-methyl-1-phenylpyridin-2[H-1]-one), on hyperpolarization-activated cation current: An additional but distinctive target. Eur. J. Pharmacol. 2020, 882, 173237. [Google Scholar] [CrossRef]
  46. Kodirov, S.A. Delineation and functions of HCN channels in neurons. Prog. Biophys. Mol. Biol. 2025, 198, 21–31. [Google Scholar] [CrossRef] [PubMed]
  47. D'Aloisio, R.; Di Antonio, L.; Toto, L.; Rispoli, M.; Di Iorio, A.; Delvecchio, G.; Mastropasqua, R. Choroidal Changes in Blood Flow in Patients with Intermediate AMD after Oral Dietary Supplement Based on Astaxanthin, Bromelain, Vitamin D3, Folic Acid, Lutein, and Antioxidants. Medicina (Kaunas) 2022, 58, 1092. [Google Scholar] [CrossRef]
  48. Ogaard, B.; Larsson, E.; Glans, R.; Henriksson, T.; Birkhed, D. Antimicrobial effect of a chlorhexidine-thymol varnish (Cervitec) in orthodontic patients. A prospective, randomized clinical trial. J. Orofac. Orthop. 1997, 58, 206−213. [Google Scholar]
  49. Kasparaviciene, G.; Kalveniene, Z.; Pavilonis, A.; Marksiene, R.; Dauksiene, J.; Bernatoniene, J. Formulation and Characterization of Potential Antifungal Oleogel with Essential Oil of Thyme. Evid. Based Complement. Alternat. Med. 2018, 2018, 9431819. [Google Scholar] [CrossRef]
  50. Aksoy, T.; Kilimcioğlu, A.A. Thymol's antileishmanial activity and its impact on host cytokine profiles: In vitro and ex vivo studies on Leishmania tropica. Parasitol. Int. 2026, 110, 103139. [Google Scholar] [CrossRef] [PubMed]
  51. Chen, C.; Liu, L.; Tang, S.; Li, D.; Dai, C. Antifungal Activity of Natural Thymol: Advances on Molecular Mechanisms and Therapeutic Potential. Biomolecules 2026, 16, 149. [Google Scholar] [CrossRef]
  52. Hoo, G.W.; Hinds, R.L.; Dinovo, E.; Renner, S.W. Fatal large-volume mouthwash ingestion in an adult: a review and the possible role of phenolic compound toxicity. J. Intensive Care Med. 2003, 18, 150–155. [Google Scholar]
  53. Dee Manuel, M.P.; Shih, Y.H.; Hsia, S.M.; Wang, T.H.; Tseng, Y.H.; Tu, M.G.; Shieh, T.M. Evaluating thymol vapor for biofilm removal and biocompatibility in curved root canal models in vitro. J. Dent. Sci. 2026, 21, 323–332. [Google Scholar] [CrossRef] [PubMed]
  54. Shen, A.Y.; Huang, M.H.; Wang, T.S.; Wu, H.M.; Kang, Y.F; Chen, CL. Thymol-evoked Ca2+ mobilization and ion currents in pituitary GH3 cells. Nat. Prod. Commun. 2009, 4, 749–752. [Google Scholar] [PubMed]
  55. Huang, M.H.; Wu, S.N.; Shen, A.Y. Stimulatory actions of thymol, a natural product, on Ca2+-activated K+ current in pituitary GH3 cells. Planta Med. 2005, 71, 1093–1098. [Google Scholar] [CrossRef]
  56. Zheng, Y.; Zhang, W.J.; Wang, X.M. Triptolide with potential medicinal value for diseases of the central nervous system. CNS Neurosci. Ther. 2013, 19, 76–82. [Google Scholar]
  57. Chen, L.W.; Wang, Y.Q.; Wei, L.C.; Shi, M.; Chan, Y.S. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. CNS Neurol. Disord. Drug Targets 2007, 6, 273–281. [Google Scholar] [CrossRef]
  58. Su, Z.; Yuan, Y.; Cao, L.; Zhu, Y.; Gao, L.; Qiu, Y.; He, C. Triptolide promotes spinal cord repair by inhibiting astrogliosis and inflammation. Glia 2010, 58, 901–915. [Google Scholar] [CrossRef]
  59. Zhang, H.; Zhu, W.; Su, X.; Wu, S.; Lin, Y.; Li, J.; Wang, Y.; Chen, J.; Zhou, Y.; Qiu, P.; Yan, G.; Zhao, S.; Hu, J.; Zhang, J. Triptolide inhibits proliferation and invasion of malignant glioma cells. J. Neurooncol. 2012, 109, 53–62. [Google Scholar] [CrossRef]
  60. Lin, J.; Chen, L.Y.; Lin, Z.X.; Zhao, M.L. The effect of triptolide on apoptosis of glioblastoma multiforme (GLM) cells. J. Int. Med. Res. 2007, 35, 637–643. [Google Scholar] [CrossRef] [PubMed]
  61. So, E.C.; Lo, Y.C.; Chen, L.T.; Kao, C.A.; Wu, S.N. High effectiveness of triptolide, an active diterpenoid triepoxide, in suppressing Kir-channel currents from human glioma cells. Eur. J. Pharmacol. 2014, 738, 332–341. [Google Scholar] [CrossRef] [PubMed]
  62. Haj-Yasein, N.N.; Jensen, V.; Vindedal, G.F.; Gundersen, G.A.; Klungland, A.; Ottersen, O.P.; Hvalby, O.; Nagelhus, E,A. Evidence that compromised K+ spatial buffering contributes to the epileptogenic effect of mutations in the human Kir4.1 gene (KCNJ10). Glia 2011, 59, 1635–1642. [Google Scholar] [CrossRef]
  63. Zhou, X.; Zhao, C.; Xu, H.; Xu, Y.; Zhan, L.; Wang, P.; He, J.; Lu, T.; Gu, Y.; Yang, Y.; Xu, C.; Chen, Y.; Liu, Y.; Zeng, Y.; Tian, F.; Chen, Q.; Xie, X.; Liu, J.; Hu, H.; Li, J.; Zheng, Y.; Guo, J.; Gao, Z. Pharmacological inhibition of Kir4.1 evokes rapid-onset antidepressant responses. Nat. Chem. Biol. 2024, 20, 857–866. [Google Scholar] [CrossRef] [PubMed]
  64. Wang, J.; Jiang, B.; Shan, Y.; Wang, X.; Lv, X; Mohamed, J; Li, H; Wang, C; Chen, J; Sun, J. Metabolic mapping of Schisandra chinensis lignans and their metabolites in rats using a metaboliomic approach based on HPLC with quadrupole time-of-flight MS/MS spectrometry. J. Sep. Sci. 2020, 43, 378–388. [Google Scholar] [CrossRef]
  65. Takanche, J.S.; Kim, J.E.; Han, S.H.; Yi, H.K. Effect of gomisin A on osteoblast differentiation in high glucose-mediated oxidative stress. Phytomedicine 2020, 66, 153107. [Google Scholar] [CrossRef]
  66. Hwang, I.S.; Kim, J.E.; Lee, Y.J.; Kwak, M.H.; Choi, Y.H.; Kang, B.C.; Hong, J.T.; Hwang, D.Y. Protective effects of gomisin A isolated from Schisandra chinensis against CCl4-induced hepatic and renal injury. Int. J. Mol. Med. 2013, 31, 888–898. [Google Scholar] [CrossRef]
  67. Kim, E.J.; Jang, M.; Lee, M.J.; Choi, J.H.; Lee, S.J.; Kim, S.K.; Jang, D.S.; Cho, I.H. Schisandra chinensis stem ameliorates 3-nitropropionic acid-induced striatal toxicity via activation of the Nrf2 pathway and inhibition of the MAPKs and NF-B pathways. Front. Pharmacol. 2017, 8, 673. [Google Scholar]
  68. Nam, S.Y.; Kim, K.Y.; Kim, M.H.; Jang, J.B.; Rah, S.Y.; Chae, H.J.; Lee, J.M.; Kim, H.M.; Jeong, H.J. Anti-inflammatory effects of a traditional Korean medicine: Ojayeonjonghwan. Pharm. Bio. 2017, 55, 1856–1862. [Google Scholar]
  69. Ye, B.H.; Lee, S.J.; Choi, Y.W.; Park, S.Y.; Kim, C.D. Preventive effect of gomisin J from Schisandra chinensis on angiotensin II-induced hypertension via an increased nitric oxide bioavailability. Hypertens. Res. 2015, 38, 169–177. [Google Scholar] [CrossRef] [PubMed]
  70. Hwang, D.; Shin, S.Y.; Lee, Y.; Hyun, J.; Yong, Y.; Park, J.C.; Lee, Y.H.; Lim, Y. A compound isolated from Schisandra chinensis induces apoptosis. Bioorg. Med. Chem. Lett. 2011, 21, 6054–6057. [Google Scholar] [CrossRef]
  71. Hong, S.H.; Li, M.; Jeung, E.B.; Lee, G.S.; Hong, E.J.; Choi, Y.W.; An, B.S. Therapeutic effects of Schisandra chinensis on the hyperprolactinemia in rat. Int. J. Oncol. 2017, 50, 1448–1454. [Google Scholar] [CrossRef]
  72. Chang, W.T.; Wu, S.N. Inhibitory Effectiveness of Gomisin A, a Dibenzocyclooctadiene Lignan Isolated from Schizandra chinensis, on the Amplitude and Gating of Voltage-Gated Na+ Current. Int. J. Mol. Sci. 2020, 21, 8816. [Google Scholar] [CrossRef]
  73. Fujita, M.; Itokawa, H.; Sashida, Y. Studies on the components of Magnolia obovate Thunb. 3. Occurrence of magnolol and hõnokiol in M. obovate and other allied plants. Yakugaku Zasshi 1973, 93, 429–434. [Google Scholar] [CrossRef]
  74. Ong, C.P.; Lee, W.L.; Tang, Y.Q.; Yap, W.H. Honokiol: a review of its anticancer potential and mechanisms. Cancers (Basel) 2019, 12, 48. [Google Scholar] [CrossRef]
  75. Lu, C.H.; Chen, S.H.; Chang, Y.S.; Liu, Y.W.; Wu, J.Y.; Lim, Y.P.; Yu, H.I.; See, Y.R. Honokiol, a potential therapeutic agent, induces cell cycle arrest and program cell death in vitro and in vivo in human thyroid cancer cells. Pharmacol. Res. 2017, 115, 288–298. [Google Scholar] [CrossRef]
  76. Tachikawa, E.; Takahashi, M.; Kashimoto, T. Effects of extract and ingredients isolated from Magnolia obovata Thunberg on catecholamine secretion from bovine adrenal chromaffin cells. Biochem. Pharmacol. 2000, 60, 433–440. [Google Scholar] [CrossRef] [PubMed]
  77. Wang, C.; Gan, D.; Wu, J.; Liao, M.; Liao, X.; Ai, W. Honokiol exerts antidepressant effects in rats exposed to chronic unpredictable mild stress by regulating brain derived neurotrophic factor level and hypothalamus-pituitary-adrenal axis activity. Neurochem. Res. 2018, 43, 1519–1528. [Google Scholar] [PubMed]
  78. Chan, M.H.; Chen, H.H.; Lo, Y.C.; Wu, S.N. Effectiveness in the Block by Honokiol, a Dimerized Allylphenol from Magnolia Officinalis, of Hyperpolarization-Activated Cation Current and Delayed-Rectifier K+ Current. Int. J. Mol. Sci. 2020, 21, 4260. [Google Scholar] [CrossRef] [PubMed]
  79. Khodir, S.A.; Sweed, E.M.; El-Haroun, H.; Abd-Elhamid, T.H.; El Derbaly, S.A.; Mahmoud, A.R.; Motawea, S.M. Honokiol ameliorates reserpine-induced fibromyalgia through antioxidant, anti-inflammatory, neurotrophic, and anti-apoptotic mechanisms. Sci. Rep. 2025, 15, 25983. [Google Scholar] [CrossRef]
  80. Shiao, M.S. Natural products of the medicinal fungus Ganoderma lucidum: occurrence, biological activities, and pharmacological functions. Chem. Rec. 2003, 3, 172–180. [Google Scholar] [CrossRef]
  81. Cör, D.; Knez, Ž.; Knez Hrnčič, M. Antitumour, antimicrobial, antioxidant and antiacetylcholinesterase effect of Ganoderma lucidum terpenoids and polysaccharides: a review. Molecules 2018, 23, 649. [Google Scholar] [CrossRef]
  82. Peng, X.; Li, L.; Dong, J.; Lu, S.; Lu, J.; Li, X.; Zhou, L.; Qiu, M. Lanostane-type triterpenoids from the fruiting bodies of Ganoderma applanatum. Phytochemistry 2019, 157, 103–110. [Google Scholar] [CrossRef]
  83. Kuok, Q.Y.; Yeh, C.Y.; Su, B.C.; Hsu, P.L.; Ni, H.; Liu, M.Y.; Mo, F.E. The triterpenoids of Ganoderma tsugae prevent stress-induced myocardial injury in mice. Mol. Nutr. Food Res. 2013, 57, 1892–1896. [Google Scholar] [CrossRef]
  84. Ma, B.; Ren, W.; Zhou, Y.; Ma, J.; Ruan, Y.; Wen, C.N. Triterpenoids form the spores of Ganoderma lucidum. N. Am. J. Med. Sci. 2011, 3, 495–498. [Google Scholar] [CrossRef] [PubMed]
  85. Lou, H.W.; Guo, X.Y.; Zhang, X.C.; Guo, L.Q.; Lin, J.F. Optimization of cultivation conditions of lingzhi or reishi medicinal mushroom, Ganoderma lucidum (Agaricomycetes) for the highest antioxidant activity and antioxidant content. Int. J. Med. Mushrooms 2019, 21, 353–366. [Google Scholar] [CrossRef] [PubMed]
  86. Liang, C.; Tian, D.; Liu, Y.; Li, H.; Zhu, J.; Li, M.; Xin, M.; Xia, J. Review of the molecular mechanisms of Ganoderma lucidum triterpenoids: ganoderic acids A, C2, D, F, DM, X and Y. Eur. J. Med. Chem. 2019, 174, 130–141. [Google Scholar] [CrossRef]
  87. Chang, W.T.; Gao, Z.H.; Lo, Y.C.; Wu, S.N. Evidence for Effective Inhibitory Actions on Hyperpolarization-Activated Cation Current Caused by Ganoderma Triterpenoids, the Main Active Constituents of Ganoderma Spores. Molecules 2019, 24, 4256. [Google Scholar] [CrossRef]
  88. Kim, A.Y.; Yun, C.I.; Lee, J.G.; Kim, Y.J. Determination and daily intake estimation of lignans in sesame seeds and sesame oil products in Korea. Foods 2020, 9, 394. [Google Scholar] [CrossRef]
  89. Dhar, P.; Chattopadhya, K.; Bhattacharyya, D.; Biswas, A.; Roy, B.; Ghosh, S. Ameliorative influence of sesame lignans on lipid profile and lipid peroxidation in induced diabetic rats. J. Agric. Food Chem. 2007, 55, 5875–5880. [Google Scholar] [CrossRef] [PubMed]
  90. Liang, Y.T.; Chen, J.; Jiao, R.; Peng, C.; Zuo, Y.; Lei, L.; Liu, Y.; Wang, X.; Ma, K.Y.; Huang, Y.; Chen, Z.Y. Cholesterol-lowering activity of sesamin is associated with down-regulation on genes of sterol transporters involved in cholesterol absorption. J. Agri. Food Chem. 2015, 63, 2963–2969. [Google Scholar] [CrossRef]
  91. Ruankham, W.; Suwanjang, W.; Wongchitrat, P.; Prachayasittikul, V.; Prachayasittikul, S.; Phopin, K. Sesamin and sesamol attenuate H2O2-induced oxidative stress on human neuronal cells via the SIRT1-SIRT3-FOXO3a signaling pathway. Nutr. Neurosci. 2021, 24, 90–101. [Google Scholar] [CrossRef]
  92. Jayaraj, P.; Narasimhulu, C.A.; Rajagopalan, S.; Parthasarathy, S.; Desikan, R. Sesamol: a powerful functional food ingredient from sesame oil for cardioprotection. Food Funct. 2020, 11, 1198–1210. [Google Scholar] [CrossRef]
  93. Kuo, P.C.; Kao, Z.H.; Lee, S.W.; Wu, S.N. Effects of Sesamin, the Major Furofuran Lignan of Sesame Oil, on the Amplitude and Gating of Voltage-Gated Na+ and K+ Currents. Molecules 2020, 25, 3062. [Google Scholar] [CrossRef]
  94. Pan, Y.; Cummins, T.R. Distinct functional alterations in SCN8A epilepsy mutant channels. J. Physiol. 2020, 598, 381–401. [Google Scholar]
  95. Djamgoz, M.B.A. Stemness of Cancer: A Study of Triple-negative Breast Cancer From a Neuroscience Perspective. Stem Cell Rev. Rep. 2025, 21, 337–350. [Google Scholar] [CrossRef]
  96. Guadano, A.; Gutierrez, C.; de La Pena, E.; Cortes, D.; Gonzalez-Coloma, A. Insecticidal and mutagenic evaluation of two annonaceous acetogenins. J. Nat. Prod. 2000, 63, 773–776. [Google Scholar] [CrossRef] [PubMed]
  97. Queiroz, E.F.; Roblot, F.; Duret, P.; Figadere, B.; Gouyette, A.; Laprevote, O.; Serani, L.; Hocquemiller, R. Synthesis, spectroscopy, and cytotoxicity of glycosylated acetogenin derivatives as promising molecules for cancer therapy. J. Med. Chem. 2000, 43, 1604–1610. [Google Scholar] [CrossRef] [PubMed]
  98. Arndt, S.; Emde, U.; Baurle, S.; Friedrich, T.; Grubert, L.; Koert, U. Quinone-annonaceous acetogenins: synthesis and complex I inhibition studies of a new class of natural product hybrids. Chemistry 2001, 7, 993–1005. [Google Scholar] [CrossRef]
  99. Shimda, H.; Grutzner, J.B.; Kozlowski, J.F.; McLaughlin, J.L. Membrane conformations and their relation to cytotoxicity of asimicin and its analogues. Biochemistry 1998, 37, 854–866. [Google Scholar] [CrossRef] [PubMed]
  100. Zhu, X.F.; Liu, Z.C.; Xie, B.F.; Li, Z.M.; Feng, G.K.; Xie, H.H.; Wu, S.J.; Yang, R.Z.; Wei, X.Y.; Zeng, Y.X. Involvement of caspase-3 activation in squamocin-induced apoptosis in leukemia cell line HL-60. Life Sci. 2002, 70, 1259–1269. [Google Scholar] [CrossRef]
  101. Wu, S.N.; Chiang, H.T.; Chang, F.R.; Liaw, C.C.; Wu, Y.C. Stimulatory effects of squamocin, an Annonaceous acetogenin, on Ca2+-activated K+ current in cultured smooth muscle cells of human coronary artery. Chem. Res. Toxicol. 2003, 16, 15–22. [Google Scholar] [CrossRef]
  102. Priyadarsini, K.I. The chemistry of curcumin: from extraction to therapeutic agent. Molecules 2014, 19, 20091–20112. [Google Scholar] [CrossRef]
  103. Meng, B.; Li, J.; Cao, H. Antioxidant and antiiflammatory activities of curcumin on diabetes mellitus and its complication. Curr. Pharm. Des. 2013, 19, 2101–2113. [Google Scholar]
  104. Jiménez-Osorio, A.S.; Monroy, A.; Alavez, S. Curcumin and insulin resistance-Molecular targets and clinical evidences. Biofactors 2016, 42, 561–580. [Google Scholar] [CrossRef]
  105. Kuo, P.C.; Yang, C.J.; Lee, Y.C.; Chen, P.C.; Liu, Y.C.; Wu, S.N. The comprehensive electrophysiological study of curcuminoids on delayed-rectifier K+ currents in insulin-secreting cells. Eur. J. Pharmacol. 2018, 819, 233–241. [Google Scholar] [CrossRef]
  106. Gutierres, V.O.; Campos, M.L.; Arcaro, C.A.; Assis, R.P.; Baldan-Cimatti, H.M.; Peccinini, R.G.; Paula-Gomes, S.; Kettelhut, I.C.; Baviera, A.M.; Brunetti, I. L: Curcumin pharmacokinetic and pharmacodynamics evidences in streptozotocin-diabetic rats support the antidiabetic activity to be via metabolite(s). Evid. Based. Complement. Alternat. Med. 2015, 2015, 678218. [Google Scholar]
  107. Lim, H.J.; Lee, J.H.; Choi, J.S.; Lee, S.K.; Kim, Y.S.; Kim, H.P. Inhibition of airway inflammation by the roots of Angelica decursiva and its constituent, columbianadin. J. Ethnopharmacol. 2014, 155, 1353–1361. [Google Scholar] [CrossRef]
  108. Yu, J.; Zhong, B.; Xiao, Q.; Du, L.; Hou, Y.; Sun, H.S.; Lu, J.J.; Chen, X. Induction of programmed necrosis: A novel anti-cancer strategy for natural compounds. Pharmacol. Ther. 2020, 214, 107593. [Google Scholar] [CrossRef] [PubMed]
  109. Chang, W.T.; Wu, S.N. Effectiveness of Columbianadin, a Bioactive Coumarin Derivative, in Perturbing Transient and Persistent INa. Int. J. Mol. Sci. 2021, 22, 621. [Google Scholar] [CrossRef] [PubMed]
  110. Wu, S.N.; Wu, Y.H.; Chen, B.S.; Lo, Y.C.; Liu, Y.C. Underlying mechanism of actions of tefluthrin, a pyrethroid insecticide, on voltage-gated ion currents and on action currents in pituitary tumor (GH3) cells and GnRH-secreting (GT1-7) neurons. Toxicology 2009, 258, 70–77. [Google Scholar] [CrossRef] [PubMed]
  111. Lin, M.H.; Lin, J.F.; Yu, M.C.; Wu, S.N.; Wu, C.L.; Cho, H.Y. Characterization in Potent Modulation on Voltage-Gated Na+ Current Exerted by Deltamethrin, a Pyrethroid Insecticide. Int. J. Mol. Sci. 2022, 23, 14733. [Google Scholar] [CrossRef]
  112. Huang, H.Y.; Huang, Y.B.; Wu, C.L.; Wu, S.N. Modulatory Impact of Tefluthrin, Telmisartan, and KB-R7943 on Voltage-Gated Na+ Currents. Biophysica 2024, 4, 488–506. [Google Scholar] [CrossRef]
  113. Hou, S.M.; Hsia, C.W.; Tsai, C.L.; Hsia, C.H.; Jayakumar, T.; Velusamy, M.; Sheu, J.R. Modulation of human platelet activation and in vivo vascular thrombosis by columbianadin: regulation by integrin IIb3 inside-out but not outside-in signals. J. Biomed. Sci. 2020, 27, 60. [Google Scholar] [CrossRef]
  114. Kang, J.I.; Hong, J.Y.; Choi, J.S.; Lee, S.K. Columbianadin Inhibits Cell Proliferation by Inducing Apoptosis and Necroptosis in HCT116 Colon Cancer Cells. Biomol. Ther. (Seoul) 2016, 24, 320–327. [Google Scholar] [CrossRef] [PubMed]
  115. Köseoğlu, B.G.; Tanrikulu, S.; Sübay, R.K.; Sencer, S. Anesthesia following overfilling of a root canal sealer into the mandibular canal: a case report. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2006, 101, 803–806. [Google Scholar] [CrossRef] [PubMed]
  116. Irie, Y.; Keung, W.M. Rhizoma acori graminei and its active principles protect PC-12 cells from the toxic effect of amyloid- peptide. Brain Res. 2003, 963, 282–289. [Google Scholar] [CrossRef]
  117. Li, J.; Liu, X.; Liu, X.; Zhou, Y.; Wang, L. Interplay between olfactory inputs and seizure regulation: Mechanisms and evidence. Epilepsy Behav. 2026, 177, 110897. [Google Scholar] [CrossRef]
  118. Müller, M.; Pape, H.C.; Speckmann, E.J.; Gorji, A. Effect of eugenol on spreading depression and epileptiform discharges in rat neocortical and hippocampal tissues. Neuroscience 2006, 140, 743–751. [Google Scholar] [CrossRef]
  119. Huang, C.W.; Chow, J.C.; Tsai, J.J.; Wu, S.N. Characterizing the effects of Eugenol on neuronal ionic currents and hyperexcitability. Psychopharmacology (Berl) 2012, 221, 575–587. [Google Scholar] [CrossRef]
  120. Teixeira-Fonseca, J.L.; Santos-Miranda, A.; da Silva, J.B.; Marques, L.P.; Joviano-Santos, J.V.; Nunes, P.I.C.; Roman-Campos, D.; Gondim, A.N.S. Eugenol interacts with cardiac sodium channel and reduces heart excitability and arrhythmias. Life Sci. 2021, 282, 119761. [Google Scholar] [CrossRef]
  121. Yang, B.H.; Piao, Z.G.; Kim, Y.B.; Lee, C.H.; Lee, J.K.; Park, K.; Kim, J.S.; Oh, S.B. Activation of vanilloid receptor 1 (VR1) by eugenol. J. Dent. Res. 2003, 82, 781–785. [Google Scholar] [CrossRef]
  122. Chung, G.; Rhee, J.N.; Jung, S.J.; Kim, J.S.; Oh, S.B. Modulation of CaV2.3 calcium channel currents by eugenol. J. Dent. Res. 2008, 87, 137–141. [Google Scholar] [CrossRef] [PubMed]
  123. Huang, C.W.; Chow, J.C.; Tsai, J.J.; Wu, S.N. Characterizing the effects of Eugenol on neuronal ionic currents and hyperexcitability. Psychopharmacology (Berl) 2012, 221, 575–587. [Google Scholar] [CrossRef] [PubMed]
  124. Li, H.F.; Chen, S.A.; Wu, S.N. Evidence for the stimulatory effect of resveratrol on Ca2+-activated K+ current in vascular endothelial cells. Cardiovasc. Res. 2000, 45, 1035–45. [Google Scholar] [CrossRef]
  125. Zhang, L.X.; Li, C.X.; Kakar, M.U.; Khan, M.S.; Wu, P.F.; Amir, R.M.; Dai, D.F.; Naveed, M.; Li, Q.Y.; Saeed, M.; Shen, J.Q.; Rajput, S.A.; Li, J.H. Resveratrol (RV): A pharmacological review and call for further research. Biomed. Pharmacother. 2021, 143, 112164. [Google Scholar] [CrossRef]
  126. Caiati, C; Jirillo, E. Cellular and Molecular Bases for the Application of Polyphenols in the Prevention and Treatment of Cardiovascular Disease. Diseases 2025, 13, 221. [Google Scholar] [CrossRef]
  127. Rao, Y.L.; Ganaraja, B.; Joy, T.; Pai, M.M.; Ullal, S.D.; Murlimanju, B.V. Neuroprotective effects of resveratrol in Alzheimer's disease. Front. Biosci. (Elite Ed) 2020, 12, 139–149. [Google Scholar] [CrossRef]
  128. Kim, H.J.; Kim, I.K.; Song, W.; Lee, J.; Park, S. The synergic effect of regular exercise and resveratrol on kainate-induced oxidative stress and seizure activity in mice. Neurochem. Res. 2013, 38, 117–122. [Google Scholar] [CrossRef] [PubMed]
  129. Almeida, E.R.; Lima-Rezende, C.A.; Schneider, S.E.; Garbinato, C.; Pedroso, J.; Decui, L.; Aguiar, G.P.S.; Müller, L.G.; Oliveira, J.V.; Siebel, A.M. Micronized Resveratrol Shows Anticonvulsant Properties in Pentylenetetrazole-Induced Seizure Model in Adult Zebrafish. Neurochem. Res. 2021, 46, 241–251. [Google Scholar] [CrossRef]
  130. Wang, Y.J.; Chan, M.H.; Chen, L.; Wu, S.N.; Chen, H.H. Resveratrol attenuates cortical neuron activity: roles of large conductance calcium-activated potassium channels and voltage-gated sodium channels. J. Biomed. Sci. 2016, 23, 47. [Google Scholar] [CrossRef]
  131. Granados-Soto, V.; Arguelles, C.F.; Ortiz, M.I. The peripheral antinociceptive effect of resveratrol is associated with activation of potassium channels. Neuropharmacology 2002, 43, 917–923. [Google Scholar] [CrossRef]
  132. Tang, C.; Wu, B.; Wu, J.; Zhang, Z.; Yu, B. Novel strategies using total gastrodin and gastrodigenin, or total gastrodigenin for quality control of Gastrodia elata. Molecules 2018, 23, 270. [Google Scholar] [CrossRef]
  133. Liu, Y.; Gao, J.; Peng, M.; Meng, H.; Ma, H.; Cai, P.; Xu, Y.; Zhao, Q.; Si, G. A review on central nervous system effect of gastrodin. Front. Pharmacol. 2018, 9, 24. [Google Scholar] [CrossRef]
  134. Yang, C.S.; Chiu, S.C.; Liu, P.Y.; Wu, S.N.; Lai, M.C.; Huang, C.W. Gastrodin alleviates seizure severity and neuronal excitotoxicities in the rat lithium-pilocarpine model of temporal lobe epilepsy via enhancing GABAergic transmission. J. Ethnopharmacol. 2021, 269, 113751. [Google Scholar] [CrossRef] [PubMed]
  135. Dai, J.; Shen, H.L.; Li, J.; Zhou, Y.; Dong, Z.X.; Zhu, X.Y. Gastrodin Attenuates Neuroinflammation and Injury in Young Rats with LiCl/Pilocarpine-Induced Status Epilepticus. Biochem. Genet. 2025, 63, 5067–5082. [Google Scholar] [CrossRef] [PubMed]
  136. Wang, D.; Liu, W.; Lu, M.; Xu, Q. Neuropharmacological effects of Gastrodia elata Blume and its active ingredients. Front. Neurol. 2025, 16, 1574277. [Google Scholar] [CrossRef]
  137. Yang, C.S.; Lai, M.C.; Liu, P.Y.; Lo, Y.C.; Huang, C.W.; Wu, S.N. Characterization of the Inhibitory Effect of Gastrodigenin and Gastrodin on M-type K+ Currents in Pituitary Cells and Hippocampal Neurons. Int. J. Mol. Sci. 2019, 21, 117. [Google Scholar] [CrossRef]
  138. Ahmad, H.; Rajagopal, K. Pharmacology of Pterocarpus marsupium Roxib. Medicinal Plant Research 2015, 5, 1–6. [Google Scholar]
  139. Tan, K.; Chen, P.W.; Li, S.; Ke, T.M.; Lin, S.H.; Yang, C.C. Pterostilbene inhibits lung squamous cell carcinoma growth in vitro and in vivo by inducing S phase arrest and apoptosis. Oncol. Lett. 2019, 18, 1631–1640. [Google Scholar] [CrossRef]
  140. Yu, C.L.; Yang, S.F.; Hung, T.W.; Lin, C.L.; Hsieh, Y.H.; Chiou, H.L. Inhibition of eIF2alpha dephosphorylation accelerates pterostilbene-induced cell death in human hepatocellular carcinoma cells in an ER stress and autophagy-dependent manner. Cell Death Dis. 2019, 10, 418. [Google Scholar] [CrossRef]
  141. Zhang, T.; Li, B.; Feng, Q.; Xu, Z.; Huang, C.; Wu, H.; Chen, Z.; Hu, L.; Gao, L.; Liu, P.; Yang, G.; Zhang, H.; Lu, K.; Li, T.; Tao, Y.; Wu, X.; Shi, J.; Zhu, W. DCZ0801, a novel compound, induces cell apoptosis and cell cycle arrest via MAPK pathway in multiple myeloma. Acta Biochim. Biophys. Sin. (Shanghai) 2019, 51, 517–523. [Google Scholar] [CrossRef] [PubMed]
  142. So, E.C.; Gao, Z.H.; Ko, S.Y.; Wu, S.N. Characterization of Effectiveness in Concerted Ih Inhibition and IK(Ca) Stimulation by Pterostilbene (Trans-3,5-dimethoxy-4'-hydroxystilbene), a Stilbenoid. Int. J. Mol. Sci. 2020, 21, 357. [Google Scholar] [CrossRef]
  143. Wu, S.N.; Chern, J.H.; Shen, S.; Chen, H.H.; Hsu, Y.T.; Lee, C.C.; Chan, M.H.; Lai, M.C.; Shie, F.S. Stimulatory actions of a novel thiourea derivative on large-conductance, calcium-activated potassium channels. J. Cell. Physiol. 2017, 232, 3409–3421. [Google Scholar] [CrossRef]
  144. Sobhani, M.; Abbas-Mohammadi, M.; Ebrahimi, S.N.; Aliahmadi, A. Tracking leading anti-Candida compounds in plant samples; Plumbago europaea. Iran. J. Microbiol. 2018, 10, 187–193. [Google Scholar]
  145. Liu, Y.; Cai, Y.; He, C.; Chen, M.; Li, H. Anticancer Properties and Pharmaceutical Applications of Plumbagin: A Review. Am. J. Chin. Med. 2017, 45, 423–441. [Google Scholar] [CrossRef]
  146. Roy, R.; Mandal, S.; Chakrabarti, J.; Saha, P.; Panda, C.K. Downregulation of Hyaluronic acid-CD44 signaling pathway in cervical cancer cell by natural polyphenols Plumbagin, Pongapin and Karanjin. Mol. Cell. Biochem. 2021, 476, 3701–3709. [Google Scholar] [CrossRef] [PubMed]
  147. Zhang, Q.; Zhao, S.; Zheng, W.; Fu, H.; Wu, T.; Hu, F. Plumbagin attenuated oxygen-glucose deprivation/reoxygenation-induced injury in human SH-SY5Y cells by inhibiting NOX4-derived ROS-activated NLRP3 inflammasome. Biosci. Biotechnol. Biochem. 2020, 84, 134–142. [Google Scholar] [CrossRef] [PubMed]
  148. Thakor, N.; Janathia, B. Plumbagin: A Potential Candidate for Future Research and Development. Curr. Pharm. Biotechnol. 2022, 23, 1800–1812. [Google Scholar] [CrossRef]
  149. Bhargava, S.K. Effect of testosterone replacement therapy on quantitative spermatogenesis following plumbagin treatment in immature rats. Acta Eur. Fertil. 1986, 17, 217–219. [Google Scholar]
  150. Shen, A.Y.; Huang, M.H.; Teng, C.M.; Wang, J.S. Inhibition of 2-P-mercaptophenyl-1,4-naphthoquinone on human platelet function. Life Sci. 1999, 65, 45–53. [Google Scholar] [CrossRef]
  151. Huang, M.H.; Wu, S.N.; Chen, C.P.; Shen, A.Y. Inhibition of Ca2+-activated and voltage-dependent K+ currents by 2-mercaptophenyl-1,4-naphthoquinone in pituitary GH3 cells: contribution to its antiproliferative effect. Life Sci. 2002, 70, 1185–1203. [Google Scholar] [CrossRef]
  152. Chen, L.; Cho, H.Y.; Chuang, T.H.; Ke, T.L.; Wu, S.N. The Effectiveness of Isoplumbagin and Plumbagin in Regulating Amplitude, Gating Kinetics, and Voltage-Dependent Hysteresis of erg-mediated K+ Currents. Biomedicines 2022, 10, 780. [Google Scholar] [CrossRef] [PubMed]
  153. Tsao, Y.C.; Chang, Y.J.; Wang, C.H.; Chen, L. Discovery of Isoplumbagin as a Novel NQO1 Substrate and Anti-Cancer Quinone. Int. J. Mol. Sci. 2020, 21, 4378. [Google Scholar] [CrossRef] [PubMed]
  154. Liu, P.Y.; Chang, W.T.; Wu, S.N. Characterization of the synergistic inhibition of IK(erg) and IK(DR) by ribociclib, a cyclin-dependent kinase 4/6 inhibitor. Int. J. Mol. Sci. 2020, 21, 8078. [Google Scholar] [CrossRef]
  155. Stojilkovic, S.S.; Tabak, J.; Bertram, R. Ion channels and signaling in the pituitary gland. Endocr. Rev. 2010, 31, 845–915. [Google Scholar] [CrossRef]
  156. Vandenberg, J.I.; Perry, M.D.; Perrin, M.J.; Mann, S.A.; Ke, Y.; Hill, A.P. hERG K+ channels: structure, function, and clinical significance. Physiol. Rev. 2012, 92, 1393–1478. [Google Scholar] [CrossRef] [PubMed]
  157. Martinson, A.S.; Van Rossum, D.B.; Diatta, F.H.; Layden, M.J.; Rhodes, S.A.; Martindale, M.Q.; Jegla, T.J. Functional evolution of Erg potassium channel gating reveals an ancient origin for IKr. Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 5712–5717. [Google Scholar] [CrossRef]
  158. Min, J.Y.; Lv, Y.; Mao, L.; Gong, Y.Y.; Gu, Q.; Wei, F. A rodent model of anterior ischemic optic neuropathy (AION) based on laser photoactivation of verteporfin. BMC Ophthalmol. 2018, 18, 304. [Google Scholar] [CrossRef]
  159. Iacono, P.; Toto, L.; Eliana, C.; Varano, M.; Parravano, M.C. Pharmacotherapy of central serous chorioretinopathy: review of the current treatments. Curr. Pharm. Des. 2019, 24, 4864–4873. [Google Scholar] [CrossRef]
  160. Isildak, H.; Schwartz, S.G.; Flynn, H.W. Pharmacotherapy of myopic choroidal neovascularization. Curr. Pharm. Des. 2019, 24, 4853–4859. [Google Scholar] [CrossRef]
  161. Tekrony, A.D.; Kelly, N.M.; Fage, B.A.; Cramb, D.T. Photobleaching kinetics of verteporfin and lemuteporfin in cells and optically trapped multilamellar vesicles using two-photon excitation. Photochem. Photobiol. 2011, 87, 853–861. [Google Scholar] [CrossRef]
  162. Nemes, A.; Fortmann, T.; Poeschke, S.; Greve, B.; Prevedello, D.; Santacroce, A.; Stummer, W.; Senner, V.; Ewelt, C. 5-ALA fluorescence in native pituitary adenoma cell lines: resection control and basis for photodynamic therapy (PDT)? PLoS One 2016, 11, e0161364. [Google Scholar] [CrossRef]
  163. Valenzeno, DP; Tarr, M. Calcium as a modulator of photosensitized killing of H9c2 cardiac cells. Phtochem. Photobiol. 2001, 74, 605–610. [Google Scholar] [CrossRef] [PubMed]
  164. Karacorlu, M.; Karacorlu, S.; Ozdemir, H. Nonarteritic anterior ischemic optic neuropathy after photodynamic therapy for choroidal neovascularization. Jpn. J. Ophthalmol. 2004, 48, 424–426. [Google Scholar] [CrossRef]
  165. Huang, M.H.; Liu, P.Y.; Wu, S.N. Characterization of Perturbing Actions by Verteporfin, a Benzoporphyrin Photosensitizer, on Membrane Ionic Currents. Front. Chem. 2019, 7, 566. [Google Scholar] [CrossRef] [PubMed]
  166. Gibault, F.; Corvaisier, M.; Bailly, F.; Huet, G.; Melnyk, P.; Cotelle, P. Non-photoinduced biological properties of verteporfin. Curr. Med. Chem. 2016, 23, 1171–1184. [Google Scholar] [CrossRef] [PubMed]
  167. Chen, Y.; Hu, Y. Photodynamic therapy for an iris metastasis from pulmonary adenocarcinoma. Photodiagnosis Photodyn. Ther. 2017, 20, 246–247. [Google Scholar] [CrossRef] [PubMed]
  168. Marks, P.V.; Belchetz, P.E.; Saxena, A.; Igbaseimokumo, U.; Thomson, S.; Nelson, M.; Stringer, M.R.; Holroyd, J.A.; Brown, S.B. Effect of photodynamic therapy on recurrent pituitary adenomas: clinical phase I/II trial--an early report. Br. J. Neurosurg. 2000, 14, 317–325. [Google Scholar] [CrossRef] [PubMed]
  169. Wu, S.N.; Wang, Y.J.; Gao, Z.H.; Liutkevičienė, R.; Rovite, V. Recent Advances in Ionic Mechanisms in Pituitary Cells: Implications for Electrophysiological and Electropharmacological Research. J. Clin. Med. 2025, 14, 3117. [Google Scholar] [CrossRef]
  170. Lin, C.Y.; Gao, Z.H.; Cheung, C.W.; So, E.C.; Wu, S.N. Modulation of Voltage-Gated Na+ Channel Currents by Small Molecules: Effects on Amplitude and Gating During High-Frequency Stimulation. Sci. Pharma 2025, 93, 33. [Google Scholar] [CrossRef]
  171. Tsuchiya, H. Membrane Interactions of Phytochemicals as Their Molecular Mechanism Applicable to the Discovery of Drug Leads from Plants. Molecules 2015, 20, 18923–66. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Graphic representation showing the five major categories of phytoconstituents and their potential modulation of ion channels. The five categories are alkaloids (pink), terpenoids (light blue), lignans and acetogenins (brown), polyphenols (orange), and other aromatic and conjugated systems (light yellow). Within each box, the phytochemicals discussed in this article are listed individually.
Figure 1. Graphic representation showing the five major categories of phytoconstituents and their potential modulation of ion channels. The five categories are alkaloids (pink), terpenoids (light blue), lignans and acetogenins (brown), polyphenols (orange), and other aromatic and conjugated systems (light yellow). Within each box, the phytochemicals discussed in this article are listed individually.
Preprints 201274 g001
Figure 2. Comparisons among effects of lutein, lutein plus oxaliplatin (OXAL), and lutein plus ivabradine on the amplitude of hyperpolarization-activated cation current (Ih) recorded from pituitary GH3 cells. In these experiments, whole-cell current recordings were performed in cells bathed in Ca2+-free Tyrode’s solution containing 1 M tetrodotoxin, and during the measurements, the recording pipette was filled up with a K+-enriched internal solution. (A) Superimposed Ih traces acquired in the control period (a, black) and during cell exposure to 3 M lutein alone (b, red) or 3 M lutein plus 10 M oxaliplatin (OXAL) (c, brown). The upper part indicates the voltage protocol (blue) imposed on the tested cell. Of note, Ih exhibits slow activation in response to sustained hyperpolarization. (B) Summary scatter graph demonstrating the effect of lutein, lutein plus OXAL, and lutein plus ivabradine on Ih amplitude (mean ± SEM; n = 7 for each point). Each amplitude was measured at the end point of the 2-sec hyperpolarizing step from −40 to −120 mV. In the experiments on lutein plus OXAL or lutein plus ivabradine, lutein was first added to the bath before OXAL or ivabradine was further applied. * Significantly different from control (p < 0.05) and ** significantly different from the lutein alone (3 M) group (p < 0.05). This figure is adapted from Ref. [37] and is published under the Creative Commons Attribution (CC BY) license.
Figure 2. Comparisons among effects of lutein, lutein plus oxaliplatin (OXAL), and lutein plus ivabradine on the amplitude of hyperpolarization-activated cation current (Ih) recorded from pituitary GH3 cells. In these experiments, whole-cell current recordings were performed in cells bathed in Ca2+-free Tyrode’s solution containing 1 M tetrodotoxin, and during the measurements, the recording pipette was filled up with a K+-enriched internal solution. (A) Superimposed Ih traces acquired in the control period (a, black) and during cell exposure to 3 M lutein alone (b, red) or 3 M lutein plus 10 M oxaliplatin (OXAL) (c, brown). The upper part indicates the voltage protocol (blue) imposed on the tested cell. Of note, Ih exhibits slow activation in response to sustained hyperpolarization. (B) Summary scatter graph demonstrating the effect of lutein, lutein plus OXAL, and lutein plus ivabradine on Ih amplitude (mean ± SEM; n = 7 for each point). Each amplitude was measured at the end point of the 2-sec hyperpolarizing step from −40 to −120 mV. In the experiments on lutein plus OXAL or lutein plus ivabradine, lutein was first added to the bath before OXAL or ivabradine was further applied. * Significantly different from control (p < 0.05) and ** significantly different from the lutein alone (3 M) group (p < 0.05). This figure is adapted from Ref. [37] and is published under the Creative Commons Attribution (CC BY) license.
Preprints 201274 g002
Figure 3. Modulation by lutein on the strength in voltage-dependent hysteresis of Ih recorded from GH3 cells. (A) Representative current traces (i.e., the relationship of forward [descending] or reverse [ascending] current versus membrane potential) of Ih evoked by the inverted double (i.e., isosceles-triangular) ramp pulse (indicated in the top part, blue) in the absence (a, black) or presence of 3 M lutein (b, red). The dashed black arrows along the current trace in the control period (i.e., lutein was not present) indicate an anti-clockwise direction of Ih trajectory in which time passes with the activated by inverted double ramp pulse, while the shaded region is the hysteretic area (area) with or without the lutein presence. Of note, Ih displays inward rectifying behavior together with voltage-dependent hysteresis. (B) Summary graph revealing effects of lutein (1 or 3 M) and lutein (3 M) plus ivabradine (3 M) on the area of voltage-dependent hysteresis. The area refers to the shaded region under the Ih curve activated during the downsloping and upsloping limbs of triangular ramp pulse (mean ± SEM; n = 7 for each point). Notably, there was an emergence of ramp pulse-induced hysteresis for Ih elicitation, and the presence of lutein was concentration-dependently able to produce a measurable reduction in the area of hysteretic current. ** Significantly different from control (p < 0.05) and * significantly different from lutein-alone (3 M) group (p < 0.05). This figure is adapted from Ref. [37] and is published under the Creative Commons Attribution (CC BY) license.
Figure 3. Modulation by lutein on the strength in voltage-dependent hysteresis of Ih recorded from GH3 cells. (A) Representative current traces (i.e., the relationship of forward [descending] or reverse [ascending] current versus membrane potential) of Ih evoked by the inverted double (i.e., isosceles-triangular) ramp pulse (indicated in the top part, blue) in the absence (a, black) or presence of 3 M lutein (b, red). The dashed black arrows along the current trace in the control period (i.e., lutein was not present) indicate an anti-clockwise direction of Ih trajectory in which time passes with the activated by inverted double ramp pulse, while the shaded region is the hysteretic area (area) with or without the lutein presence. Of note, Ih displays inward rectifying behavior together with voltage-dependent hysteresis. (B) Summary graph revealing effects of lutein (1 or 3 M) and lutein (3 M) plus ivabradine (3 M) on the area of voltage-dependent hysteresis. The area refers to the shaded region under the Ih curve activated during the downsloping and upsloping limbs of triangular ramp pulse (mean ± SEM; n = 7 for each point). Notably, there was an emergence of ramp pulse-induced hysteresis for Ih elicitation, and the presence of lutein was concentration-dependently able to produce a measurable reduction in the area of hysteretic current. ** Significantly different from control (p < 0.05) and * significantly different from lutein-alone (3 M) group (p < 0.05). This figure is adapted from Ref. [37] and is published under the Creative Commons Attribution (CC BY) license.
Preprints 201274 g003
Figure 4. Effect of lutein on sag potential recorded from GH3 cells. In these current-clamp potential recordings, cells were immersed in normal Tyrode’s solution, which contained 1.8 mM CaCl2 and 1 M tetrodotoxin, and a long-lasting hyperpolarizing current stimulus with a duration of 2 sec was applied. (A) Representative potential traces acquired in the control period (a, black) and during cell exposure to 1 M lutein (b, blue) or 3 M lutein (c, red). The top part indicates the long-step current injection imposed over the tested cell. (B) Summary scatter graph showing the ability of lutein to alter the amplitude of sag potential (mean ± SEM; n = 7 for each point). Under the current-clamp configuration, the magnitude of sag potential (i.e., the difference between the start and end of hyperpolarizing current stimulus) was acquired with or without the presence of lutein. * Significantly different from control (p < 0.05) and ** significantly different from the lutein-alone (1 M) group (p < 0.05). This figure is adapted from Ref. [37] and is published under the Creative Commons Attribution (CC BY) license.
Figure 4. Effect of lutein on sag potential recorded from GH3 cells. In these current-clamp potential recordings, cells were immersed in normal Tyrode’s solution, which contained 1.8 mM CaCl2 and 1 M tetrodotoxin, and a long-lasting hyperpolarizing current stimulus with a duration of 2 sec was applied. (A) Representative potential traces acquired in the control period (a, black) and during cell exposure to 1 M lutein (b, blue) or 3 M lutein (c, red). The top part indicates the long-step current injection imposed over the tested cell. (B) Summary scatter graph showing the ability of lutein to alter the amplitude of sag potential (mean ± SEM; n = 7 for each point). Under the current-clamp configuration, the magnitude of sag potential (i.e., the difference between the start and end of hyperpolarizing current stimulus) was acquired with or without the presence of lutein. * Significantly different from control (p < 0.05) and ** significantly different from the lutein-alone (1 M) group (p < 0.05). This figure is adapted from Ref. [37] and is published under the Creative Commons Attribution (CC BY) license.
Preprints 201274 g004
Figure 5. Docking interaction between the triptolide molecule and the KCNJ10 (or Kir4.1-encoded) channel. The left graph refers to the docking prediction between triptolide and the KCNJ10 channel. The protein structure of KCNJ10 was obtained from the Protein Data Bank (PDB ID: 815M), and the three-dimensional chemical structure of triptolide was retrieved from PubChem (Compound CID: 107985). On the left, the red dashed box highlights a snapshot of triptolide engaging hydrophobic interactions and forming hydrogen bonds with the channel, which is enlarged and illustrated on the right. The green dashed line indicates hydrogen bond formation, with bond lengths estimated at 3.06 and 3.08 Å. Of note, in this and the following figures showing predicted docking, the red arcs, with spokes pointing toward the triptolide molecule, denote hydrophobic contacts, and the corresponding graph in the right panel indicates an expanded display of red dashed box with a curve arrow in the left panel. .
Figure 5. Docking interaction between the triptolide molecule and the KCNJ10 (or Kir4.1-encoded) channel. The left graph refers to the docking prediction between triptolide and the KCNJ10 channel. The protein structure of KCNJ10 was obtained from the Protein Data Bank (PDB ID: 815M), and the three-dimensional chemical structure of triptolide was retrieved from PubChem (Compound CID: 107985). On the left, the red dashed box highlights a snapshot of triptolide engaging hydrophobic interactions and forming hydrogen bonds with the channel, which is enlarged and illustrated on the right. The green dashed line indicates hydrogen bond formation, with bond lengths estimated at 3.06 and 3.08 Å. Of note, in this and the following figures showing predicted docking, the red arcs, with spokes pointing toward the triptolide molecule, denote hydrophobic contacts, and the corresponding graph in the right panel indicates an expanded display of red dashed box with a curve arrow in the left panel. .
Preprints 201274 g005
Figure 6. Docking result of NaV1.7 (SCN9A) and gomisin A. The protein structure of SCN9A was obtained from PDB (PDB ID: 6N4Q) and the three-dimensional structure of gomisin A was from PubChem (Compound CID: 15608605). The structure of SCN9A was optimally docked with gomisin A through PyRx in the red dashed box of the left side.
Figure 6. Docking result of NaV1.7 (SCN9A) and gomisin A. The protein structure of SCN9A was obtained from PDB (PDB ID: 6N4Q) and the three-dimensional structure of gomisin A was from PubChem (Compound CID: 15608605). The structure of SCN9A was optimally docked with gomisin A through PyRx in the red dashed box of the left side.
Preprints 201274 g006
Figure 7. Concentration-dependent inhibition of hyperpolarization-activated cation current (Ih) by honokiol (HNK) in GH3 cells. (A) Representative Ih traces obtained in the absence and presence of honokiol. In these experiments, we bathed cells in Ca2+-free Tyrode’s solution containing 1 M tetrodotoxin, the recording electrode was filled with a K+-containing solution, and the hyperpolarizing pulses from −40 to −120 mV were applied with a duration of 2 sec. Current trace labeled a is the control, and that labeled b or c was obtained after the addition of 3 M honokiol or 10 M honokiol, respectively. The upper part denotes the voltage-clamp protocol applied. (B) Concentration-response relationship for honokiol-induced inhibition of Ih (mean ± SEM; n=8 for each data point). The sigmoidal curve represents best fit to the Hill equation, and effective IC50 value was estimated to be 2.1 M. This figure is adapted from Ref. [78] and is published under the Creative Commons Attribution (CC BY) license.
Figure 7. Concentration-dependent inhibition of hyperpolarization-activated cation current (Ih) by honokiol (HNK) in GH3 cells. (A) Representative Ih traces obtained in the absence and presence of honokiol. In these experiments, we bathed cells in Ca2+-free Tyrode’s solution containing 1 M tetrodotoxin, the recording electrode was filled with a K+-containing solution, and the hyperpolarizing pulses from −40 to −120 mV were applied with a duration of 2 sec. Current trace labeled a is the control, and that labeled b or c was obtained after the addition of 3 M honokiol or 10 M honokiol, respectively. The upper part denotes the voltage-clamp protocol applied. (B) Concentration-response relationship for honokiol-induced inhibition of Ih (mean ± SEM; n=8 for each data point). The sigmoidal curve represents best fit to the Hill equation, and effective IC50 value was estimated to be 2.1 M. This figure is adapted from Ref. [78] and is published under the Creative Commons Attribution (CC BY) license.
Preprints 201274 g007
Figure 8. Predicted docking between the HCN3 channel and the honokiol molecule. The left panel depicts the HCN3-channel protein structure acquired from PDB (PDB ID: 8IO3), and the three-dimensional structure of honokiol from PubChem (Compound CID: 72303). PyRx software was used to show that the HCN3 channel structure can be optimally docked by the honokiol molecule. The right panel depicts an expansion of the red dashed box with an curved arrow in the left panel. This diagram of the interaction between the HCN3 channel and the honokiol was generated using LigPlot+.
Figure 8. Predicted docking between the HCN3 channel and the honokiol molecule. The left panel depicts the HCN3-channel protein structure acquired from PDB (PDB ID: 8IO3), and the three-dimensional structure of honokiol from PubChem (Compound CID: 72303). PyRx software was used to show that the HCN3 channel structure can be optimally docked by the honokiol molecule. The right panel depicts an expansion of the red dashed box with an curved arrow in the left panel. This diagram of the interaction between the HCN3 channel and the honokiol was generated using LigPlot+.
Preprints 201274 g008
Figure 9. Molecular docking analysis of honokiol with superoxide dismutase. The protein structure of superoxide dismutase was acquired from PDB (PDB: 1DO5). The structure of superoxidase dismutase was docked with the honokiol molecule by using PyRx software, as indicated in the left side. The diagram of the interaction between superoxide peroxide protein and the honokiol molecule was generated by LigPlot+ (right side).
Figure 9. Molecular docking analysis of honokiol with superoxide dismutase. The protein structure of superoxide dismutase was acquired from PDB (PDB: 1DO5). The structure of superoxidase dismutase was docked with the honokiol molecule by using PyRx software, as indicated in the left side. The diagram of the interaction between superoxide peroxide protein and the honokiol molecule was generated by LigPlot+ (right side).
Preprints 201274 g009
Figure 10. Effect of pterostilbene (PTER) on the current-voltage (I-V) relationships of Ih in GH3 cells. Current traces were recorded during 2-sec voltage steps to a family of membrane potentials ranging between −130 and −40 mV in 10-mV steps from a holding potential of −40 mV, as indicated in the uppermost part of (A). (A) Representative Ih traces achieved under the control condition (i.e., pterostilbene was not present) (upper) and during the exposure to 1 M pterostilbene (lower). Arrowhead in each panel depicts the zero-current level and the calibration mark shown in the right lower side applies to all current traces. Of note, there are varying durations in voltage-clamp profile for better illustration. (B) Averaged I-V relations of Ih achieved in the absence (■) and presence (□) of 1 M pterostilbene (mean ± SEM; n = 9 for each data point). Current amplitude was measured at the end of each voltage step. This figure is adapted from Ref. [142] and is published under the Creative Commons Attribution (CC BY) license.
Figure 10. Effect of pterostilbene (PTER) on the current-voltage (I-V) relationships of Ih in GH3 cells. Current traces were recorded during 2-sec voltage steps to a family of membrane potentials ranging between −130 and −40 mV in 10-mV steps from a holding potential of −40 mV, as indicated in the uppermost part of (A). (A) Representative Ih traces achieved under the control condition (i.e., pterostilbene was not present) (upper) and during the exposure to 1 M pterostilbene (lower). Arrowhead in each panel depicts the zero-current level and the calibration mark shown in the right lower side applies to all current traces. Of note, there are varying durations in voltage-clamp profile for better illustration. (B) Averaged I-V relations of Ih achieved in the absence (■) and presence (□) of 1 M pterostilbene (mean ± SEM; n = 9 for each data point). Current amplitude was measured at the end of each voltage step. This figure is adapted from Ref. [142] and is published under the Creative Commons Attribution (CC BY) license.
Preprints 201274 g010
Figure 11. Stimulatory effect of pterostilbene (PTER) on Ca2+-activated K+ current (IK(Ca)) identified in GH3 cells. This set of whole-cell current recordings was conducted in cells suspended in normal Tyrode’s solution which contained 1.8 mM CaCl2. (A) Representative IK(Ca) traces obtained during the voltage steps to various membrane potentials between 0 and +50 mV in 10-mV steps from a holding potential of 0 mV (as indicated in the uppermost part of (A)). Records shown in the upper and lower panels were obtained under control condition and during the exposure to 3 M pterostilbene, respectively. The uppermost part depicts the voltage pulses applied. The red dashed curved arrow indicates that the amplitude of IK(Ca) increases as the cell membrane depolarizes, demonstrating its outwardly rectifying properties. (B) Averaged I-V relations of IK(Ca) obtained in the control (), during the exposure to 3 M pterostilbene (), and after washout of the agent () (mean ± SEM; n = 8 for each data point). This figure is adapted from Ref. [142] and is published under the Creative Commons Attribution (CC BY) license.
Figure 11. Stimulatory effect of pterostilbene (PTER) on Ca2+-activated K+ current (IK(Ca)) identified in GH3 cells. This set of whole-cell current recordings was conducted in cells suspended in normal Tyrode’s solution which contained 1.8 mM CaCl2. (A) Representative IK(Ca) traces obtained during the voltage steps to various membrane potentials between 0 and +50 mV in 10-mV steps from a holding potential of 0 mV (as indicated in the uppermost part of (A)). Records shown in the upper and lower panels were obtained under control condition and during the exposure to 3 M pterostilbene, respectively. The uppermost part depicts the voltage pulses applied. The red dashed curved arrow indicates that the amplitude of IK(Ca) increases as the cell membrane depolarizes, demonstrating its outwardly rectifying properties. (B) Averaged I-V relations of IK(Ca) obtained in the control (), during the exposure to 3 M pterostilbene (), and after washout of the agent () (mean ± SEM; n = 8 for each data point). This figure is adapted from Ref. [142] and is published under the Creative Commons Attribution (CC BY) license.
Preprints 201274 g011
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2026 MDPI (Basel, Switzerland) unless otherwise stated